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�.�. Cancer and the concept of immunoediting
The idea that the immune system is involved in the repression of cancer was conceived in 
the early ��th century and together with the discovery of tumor-associated antigens has led 
to the hypothesis of cancer immune surveillance, postulated in ���� by Burnet¹, which stated 
“In large, long-lived animals, like most of the warm-blooded vertebrates, inheritable genetic 
changes must be common in somatic cells and a proportion of these changes will represent a 
step toward malignancy. It is an evolutionary necessity that there should be some mechanism 
for eliminating or inactivating such potentially dangerous mutant cells and it is postulated 
that this mechanism is of immunological character.” In recent years this hypothesis has been 
reﬁned to reﬂect the interaction between tumors and the immune system, resulting in the 
concept of immunoediting. This is a dynamic process divided into three phases: elimination, 
equilibrium and escape.²�³
�.�.� Elimination
The elimination phase of immunoediting is the same process as described in the initial 
immune surveillance hypothesis. It includes both an innate and an adaptive immune response 
to tumor cells by contributors including natural killer (NK) cells, T helper � (Th�) cells and 
CD�-positive cytotoxic T cells (CTL).²�⁴
A major factor in the elimination process is interferon gamma (IFNγ).⁵ It can induce anti-
tumor eﬀector functions by activating cytocidal activity in macrophages and by stimulating 
NK cells,⁶ leading to perforin-, Fas- and TRAIL-mediated killing of tumor cells and subsequent 
release of tumor-associated antigens.⁷ – ⁹ NK cells in turn will produce more proinﬂammatory 
cytokines. Another result of IFNγ production and NK cell activation is the maturation of den-
dritic cells, upregulation of the antigen processing and presentation pathway and subsequent 
activation of the adaptive immune response.¹⁰
The adaptive immune response is usually targeted to tumor-associated antigens: diﬀer-
entiation antigens, mutated self-antigens, overexpressed antigens, cancer-testis antigens or 
viral antigens.¹¹�¹² B-cell lymphomas can present their own idiotype as antigens.¹³�¹⁴ Both CD�-
positive Th� cells and CD�-positive CTL eﬀector cells are needed to raise an eﬀective anti-
tumor immune response (F����� �). Naive CD�-positive T cells have to receive three signals 
to develop eﬀector functions: recognition of the antigen in the context of human leukocyte 
antigen (HLA) class I presented on an antigen-presenting cell (APC), costimulation by liga-
tion of CD�� with CD��/�� and the presence of an inﬂammatory cytokine (IL-�� or type I 
interferon).¹⁵�¹⁶ A�er initial clonal expansion, the eﬀector T cells go into a state of ‘split anergy’ 
termed activation-induced non-responsiveness (AINR), where they retain their eﬀector func-











































Figure 1. Simpliﬁed overview of the adaptive immune system cascade in the elimination 
phase
Antigen-presenting cells (APC) present peptides derived from tumor-associated antigens to T cells. When presented in the 
context of HLA class I, these peptides will be recognized by the T-cell receptor (TCR) on CD8-positive cytotoxic T cells (CTL). 
After additional costimulatory signals such as CD28 ligation and the presence of cytokines, an eﬀector phase will develop in 
which CTL can recognize and lyse the tumor cells. When presented in the context of HLA class II, the peptides will be recog-
nized by CD4-positive T helper cells (Th), and depending on the cytokines present either a Th1 or a Th2 response develops. A 
Th1 response mainly stimulates APC antigen presentation and CTL proliferation, while a Th2 response mainly causes antibody 
production and the stimulation of eosinophils.
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by IL-�. The necessary cytokines can be provided by activated CD�-positive Th� cells either 
directly (IL-�) or through stimulation of APCs to produce IL-�� and IFNα/β.¹⁷
In addition to providing help to CTL, Th� cells can also directly induce apoptosis of tumor 
cells through the Fas/FasL pathway. In lymphoma, Th�-expressed CD��L will interact with 
CD�� on the lymphoma cell, leading to upregulation of Fas on the lymphoma cell and induc-
tion of apoptosis by FasL ligation.¹⁸
�.�.� Equilibrium
If not all the tumor cells are eliminated, the elimination phase will be followed by an 
equilibrium phase. Tumor cells are o�en genetically instable and will continue to evolve and 
accumulate changes during this phase.¹⁹�²⁰ The immune system will eliminate susceptible 
tumor clones and so exerts a selective pressure. The constant evolution of the tumor cells will 
eventually give rise to tumor clones that are able to avoid, suppress or resist the immune sur-
veillance. At this point the immune system will no longer be able to control tumor progression 
and the tumor will enter the escape phase.³
�.�.� Escape
Tumor cells that survive the equilibrium phase enter the escape phase. In this phase the 
tumor can progress without being restrained by the immune response. Tumor cells can escape 
the immune system by avoiding, suppressing or resisting an immune reaction.
Avoiding immune recognition
A well documented immune escape mechanism is downregulation of HLA proteins on the 
tumor cells (reviewed in ref. ��). HLA class I proteins present antigens to CD�-positive T cells 
while HLA class II proteins present antigens to CD�-positive T cells. In the absence of HLA 
proteins, tumor-associated antigens cannot be presented to the immune system. Downregula-
tion or complete loss of HLA expression can be achieved by diﬀerent mechanisms, which will 
be discussed in more detail in paragraph �.�.
Accumulation of mutations in a tumor-associated antigen (antigenic dri�) can also help 
to avoid the immune system because the tumor-speciﬁc cytotoxic T cells will no longer rec-
ognize it.²²
Suppressing the immune reaction
Some tumors produce immunosuppressive factors (e.g. IL-��, TGFβ, galectin-�, gangliosides 
or indoleamine �,�-dioxygenase (IDO)) or express negative costimulatory signals (B� : CTLA, 
PD-�L : PD-�, FasL : Fas) to inhibit activation of T cells and dendritic cells (reviewed in ref. 
��). Speciﬁc cell populations can also contribute to the immune-suppressive environment, 
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including regulatory CD�-positive T cells,²⁴�²⁵ myeloid suppressor cells²⁶ and tumor-associ-
ated macrophages (TAM). TAMs are M� macrophages which have an IL-����� IL-����� IL-������ 
phenotype, produce TGFβ and can skew the immune response towards a Th� proﬁle. In many 
human tumors TAMs are associated with poor prognosis.²⁷
Resisting apoptosis induced by immune cells
Tumors that do not avoid immune recognition or suppress the immune reaction can become 
resistant to the eﬀects of the immune reaction by being resistant to perforin-/Fas-/TRAIL-
mediated apoptosis. This can be achieved by mutations in molecules as Fas,²⁸�²⁹ DR�³⁰ or cas-
pase �,³¹ by overexpression of anti-apoptotic proteins such as FLIP,³² Bcl�,³³�³⁴ Bcl-Xl,³⁵ IP�³⁶ or 
survivin,³⁷ or by the expression of death ligand decoy receptors.³⁸
�.�. Human Leukocyte Antigen
�.�.� The role of HLA in the human immune system
The adaptive immune system is designed to protect the human body from harmful agents. 
These agents can be pathogens, such as bacteria or viruses, as well as altered self cells express-
ing abnormal proteins, such as tumor cells.
When cells become infected or transform into tumor cells, foreign antigens will be pres-
ent in the cytosol or the nucleus. To eradicate the cells, these endogenous foreign antigens 
will be processed and presented by HLA class I proteins to CD�-positive cytotoxic T cells 
(F����� �).³⁹ HLA class I is expressed on the surface of almost all nucleated cells, although the 
levels of expression may vary between tissues.⁴⁰ However, for the initiation phase of the CTL 
response it is important that a foreign peptide is presented to the naïve CD�-positive T cell by 
a professional APC such as a dendritic cell, because these cells can deliver the costimulatory 
signals needed to activate the T cell. If the infected or transformed cell is not a professional 
APC itself, the antigen can be presented by APCs through a process called cross-presentation 
(see paragraph �.�.�). In the subsequent eﬀector phase of the response, the primed CTL will 
recognize the same peptide-HLA complex expressed on the infected or transformed cells and 
subsequently destroy these cells.⁴¹
In most bacterial infections the pathogens will not enter the cells. Eradication of these 
extracellular pathogens requires professional APCs that can internalize these exogenous anti-
gens, process them and present them to CD�-positive T helper cells in the context of HLA 
class II proteins, eventually resulting in the production of antibodies against the extracellular 
pathogen (F����� �).⁴² HLA class II is therefore expressed constitutively on professional APCs 
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such as dendritic cells, macrophages and B cells. Under inﬂammatory conditions, expression 
of HLA class II can also be induced on other cell types such as epithelial or endothelial cells by 
IFNγ and other cytokines.⁴⁰ A�er recognition of a foreign peptide by CD�-positive T helper 
cells a Th� or Th� response will develop, depending on the cytokines present.⁴³ Both will 
eventually lead to the production of antibodies against the foreign antigen; in addition the 
Th� response can stimulate proliferation and activation of CTLs through ligation of costimu-
latory molecules and production of cytokines.⁴⁴
To induce an eﬃcient CTL response to an endogenous antigen a Th� response, and thus 
presentation of the antigen by HLA class II proteins, is necessary.⁴⁵ Presentation of an endog-
enous antigen by HLA class II could be mediated by cross-presentation or autophagy (see 
paragraph �.�.�).
�.�.� Antigen processing and presentation
Class I
HLA class I molecules are transmembrane heterodimers consisting of the polymorphic 
class I heavy chain, encoded by the HLA class I genes on chromosome �p��.�, and the invari-
ant beta-�-microglobulin (β�m) light chain, encoded by a gene on chromosome ��q��. Newly 
synthesized class I heavy chain is transported to the endoplasmic reticulum (ER) where it is 
associated with chaperone protein calnexin (F����� �). When it is properly folded it binds 
β�m to form an unstable unloaded class I molecule. To help stabilize the molecule it is then 
incorporated in the peptide binding complex involving calreticulin, Erp��, TAP and tapasin. 
Endogenous peptides are degraded by the immunoproteosome and aminopeptidases and 
transported by TAP to the ER lumen. When an appropriate peptide binds and empty HLA 
class I molecule, the loaded HLA class I molecule dissociates from the peptide binding com-
plex and is transported to the cell surface (reviewed in ref. ��).
In the alternative cross-presentation pathway, peptides are derived from exogenous 
sources. Examples are antigens derived from apoptotic cells that can enter the endocytic route 
of dendritic cells, or antigens present in neighboring cells which can be transferred by direct 
cell-cell contact such as through gap junctions.⁴⁶
Class II
HLA class II molecules are transmembrane heterodimers consisting of the class II α and β 
chains, both encoded by HLA class II genes on chromosome �p��.�. Newly synthesized class 
II heterodimers are transported to the ER where they associate with the invariant chain (Ii) 
to prevent premature loading of the HLA molecule (F����� �). The invariant chain also tar-
gets the HLA molecule to the endocytic loading compartment, where it is cleaved by cathep-
sins leaving only a small part of Ii, the class II-associated Ii peptide (CLIP), bound in the 




















Figure 2. Classical HLA class I and class II antigen processing and presentation pathways
HLA class I proteins associate with the peptide loading complex in the endoplasmic reticulum (ER). Endogenous antigens 
are processed by the immunoproteosome and aminopeptidases into small peptides which are transported into the ER by 
TAP. There they bind to HLA class I molecules, which dissociate from the peptide loading complex and are transported to the 
cell surface. HLA class II proteins are targeted to an endocytic loading compartment. Exogenous antigens are processed in 
endosomes by endosomal proteases and the endosomes containing the processed peptides fuse with the endocytic loading 
compartment. HLA-DM helps select appropriate peptides which then are exchanged with CLIP. HLA-peptide complexes are 
then transported to the cell surface.
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then releases CLIP and stabilizes the empty HLA molecule. The endocytic loading compart-
ment fuses with endosomes containing exogenous antigens or endogenous transmembrane 
or secreted proteins. These are processed by endocytic proteases to yield peptides appropriate 
for loading onto HLA class II molecules. HLA-DM acts as a peptide selector, allowing only 
peptides with high aﬃnity to bind the HLA class II molecule. The loaded HLA molecules are 
then transported to the cell surface (reviewed in ref ��).
HLA class II proteins can also present peptides derived from endogenous cytosolic pro-
teins, either through cross-presentation of apoptotic cell debris, or through autophagy.⁴⁸ 
In B cells another non-classical HLA class II protein is expressed. HLA-DO modiﬁes the func-
tion of HLA-DM⁴⁹ and when DO:DM ratio is high presentation of antigens taken up through 
the B-cell receptor is favored over presentation of non-speciﬁc antigens.⁵⁰
�.�.� The human HLA region at chromosome �p��.�
The HLA genes are located in a cluster at chromosome �p��.�, named the HLA region (or 
MHC region). It spans �.� Mb and can be divided in � subregions: class I, class III and class 
II from telomere to centromere (F����� �). It is the most gene-dense region of the genome 
and contains ��� genes of which about ��� are expressed. Immune-related genes are over-
represented, comprising roughly ��% of the expressed genes in the region. The class I region 
contains the genes for the classical class I heavy chain HLA-A, -B and -C proteins and the 
non-classical class I heavy chain HLA-E, -F and -G proteins. The class III region genes include 
those involved in the complement cascade, stress response, leukocyte maturation, immune 
regulation and inﬂammation. The class II region contains the genes for classical class II HLA-
DR, -DP and -DQ proteins, as well as genes encoding components of the antigen processing 
machinery such as non-classical HLA-DM and -DO, TAP and the immunoproteosome com-
ponents LMP� and LMP�.⁵¹
The HLA class I and class II proteins are highly polymorphic. This polymorphism is pres-
ent at multiple levels from alleles to the population, and is conserved through evolution to 
allow immune responses against a vast array of pathogens and to minimalize the possibility 
that one pathogen can eradicate an entire population.⁵² At the moment of writing this thesis, 
in November ����, about ���� HLA class I and II alleles are known and each year several 
hundred additional alleles are discovered.⁵³ The combination of alleles for each locus in the 
HLA region on a single chromosome makes up the HLA haplotype. The maternal and pater-
nal haplotypes form the HLA genotype of an individual. All HLA genes are codominantly 
expressed, making up the phenotype of an individual. An extra level of polymorphism is 
provided by the HLA-DRB region, where diﬀerent haplotype groups exist diﬀering in the 










































Figure 3. HLA region at chromosome 6p21.3
Schematic representation of the HLA region and the division into class I, III and II. All classical and non-classical HLA genes are 
indicated, as well as a selection of genes involved in antigen processing or other immune-related genes.
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�.�.� Regulation of HLA expression
HLA proteins are not all equally expressed, and expression levels also vary between tissue 
types. Of the HLA class I proteins, HLA-A and HLA-B are more eﬃciently expressed than 
HLA-C. Of the class II proteins, HLA-DR is most highly expressed. The activity of the class I 
promoter is regulated by NFκB and proteins of the IRF-family, as well as by the class II trans-
activator (CIITA). CIITA is the master regulator of HLA class II expression. The expression of 
CIITA itself, and so indirectly also HLA class II expression, is regulated by IFNγ. Both HLA 
class II and CIITA can also be regulated epigenetically.⁴⁰
�.�.� Avoiding the immune response by downregulation of HLA expression
As discussed in the previous paragraph, tumors can avoid recognition by the immune 
system through downregulation or complete loss of HLA expression. Like almost all normal 
nucleated cells, tumor cells express HLA class I. Expression can be downregulated on several 
levels, from loss of one allele to complete loss of all HLA class I proteins (reviewed in ref. ��). 
Loss of single alleles can be caused by small deletions or mutations,⁵⁶�⁵⁷ while loss of a com-
plete haplotype is usually caused by larger hemizygous deletions or mitotic recombination.⁵⁸ 
Loss of expression of all class I proteins can be caused by loss or mutation of the β�m gene⁵⁹ 
or by regulatory defects such as hypermethylation of the promoter regions of the HLA-A, -B 
and -C genes.⁶⁰ Defects in the antigen processing pathway, such as downregulation of TAP or 
LMP genes, also result in complete loss of HLA class I expression.⁶¹�⁶²
HLA class I proteins inhibit NK-cell cytolytic activity by binding to inhibitory receptors 
on NK cells, such as KIRs⁶³ and CD��.⁶⁴ Tumors that have lost expression of HLA class I thus 
need additional mechanisms to prevent lysis by NK cells,⁶⁵�⁶⁶ such as expression of inhibitory 
ligands such as HLA-E or HLA-G⁶⁷ or expression of soluble MICA or MICB which are ligands 
for the NK cell activating receptor NKG�D. These soluble ligands induce internalization and 
degradation of NKG�D and thus prevent activation of NK cells.⁶⁸
B-cell lymphomas can also downregulate the expression of HLA class II. Mechanisms 
involved can be hemi- or homozygous deletions,⁶⁹ defects in CIITA expression,⁷⁰ or hyper-
methylation of the class II genes.⁷¹ Defects in the IFNγ signaling pathway will result in loss 
of CIITA and thus loss of class II expression. Although tumor-associated antigens are usually 
endogenous and presented by HLA class I proteins, HLA class II proteins can present them 
through cross-presentation or autophagy. Downregulation of HLA class II thus prevents the 




�.�. Diﬀuse large B-cell lymphoma
Diﬀuse large B-cell lymphoma (DLBCL) constitutes �� – ��% of B-cell non-Hodgkin lym-
phoma cases, with involvement of extranodal sites such as the gastro-intestinal tract, skin, 
testis, central nervous system (CNS) and bone in up to ��% of cases. It is a highly heteroge-
neous disease regarding clinical and molecular characteristics. According to the current World 
Health Organization (WHO) classiﬁcation there are � morphological subtypes: centroblastic, 
immunoblastic, anaplastic and T-cell/histiocyte-rich.⁷² Cases are stratiﬁed into risk groups 
using the International Prognostic Index (IPI) which is based on patient age and performance 
status, Ann Arbor stage, involvement of extranodal sites and level of lactate dehydrogenase 
(LDH).⁷³ Current treatment protocols consist of CHOP chemotherapy with added rituximab 
(anti-CD��).⁷⁴
Recent research has focused on the molecular basis of the clinical heterogeneity in DLBCL. 
One of the major studies compared gene expression proﬁles between DLBCL cases and nor-
mal B-cell subsets, resulting in the deﬁnition of two DLBCL subtypes with diﬀerent clinical 
outcome: one with an expression proﬁle resembling germinal center B cells and a favorable 
clinical outcome (GCB subtype) and another resembling in vitro activated B cells and with an 
aggressive clinical behavior and worse prognosis (ABC subtype).⁷⁵ Both subtypes can also be 
distinguished by immunohistochemistry: GCB-DLBCL express one or both of the GC markers 
CD�� and Bcl�, and lack expression of MUM� (IRF�), while ABC-DLBCL lack CD�� expres-
sion but do express MUM�.⁷⁶�⁷⁷ Further study of these subtypes revealed diﬀerences in chro-
mosomal aberrations and oncogenic mechanisms that might be the underlying cause of the 
diﬀerent clinical characteristics of these two subtypes (T���� �).⁷⁸ A hallmark feature of ABC-
DLBCL is constitutive activation of NFκB, which is essential for proliferation and survival of 
these lymphomas.⁷⁹
Apart from GCB and ABC subtype characteristics, some �� other potential molecular 
indicators of prognosis have been reported including molecules involved in the cell cycle, 
apoptosis, B-cell diﬀerentiation, adhesion and angiogenesis (reviewed in ref. ��). One of the 
indicators of poor prognosis is loss of HLA class II expression.⁸¹�⁸² DLBCL (and B-cell lympho-
mas in general) are diﬀerent from other tumors because the lymphoma cells are derived from 
antigen-presenting cells. Lymphoma cells themselves are therefore capable of presenting their 
own tumor-associated antigens to the immune system in the context of both HLA class I and 
class II. Loss of expression of HLA class II proteins on the lymphoma cells provides the lym-
phoma with an immune escape mechanism as discussed in paragraph �.�.
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�.� Immune-privileged site-associated DLBCL
�.�.�. Immune privilege
Although the inﬂammatory immune response usually acts to protect the body from harm-
ful infections, the immune response itself can also be harmful. In certain sites such as the eye, 
CNS, testis and the human embryo/fetus the tissue damage caused by an immune response 
could have devastating eﬀects. The ﬁrst experimental evidence for the absence or limitation of 
the immune response in these sites came from the observation that gra�s that were genetically 
diﬀerent from the accepting tissue showed prolonged survival when transplanted into these 
sites, as compared to other sites. Therefore these sites were ‘immune privileged’.⁸³
Historically, it was thought that immune privilege was a passive mechanism, in which the 
immune system had no access to the antigens because of the presence of a blood-organ barrier 
or the absence of eﬀerent lymphatics. However, in both CNS and testis the blood-organ bar-
rier is not completely impermeable for the cells of the immune system. In addition, immune 
privilege in the testis extends to the testicular interstitium, which is not protected by the 
blood-testis barrier.⁸⁴�⁸⁵ It is now known that immune privilege is actively maintained by mul-
tiple mechanisms that suppress immunity and promote tolerance. These include production 
of anti-inﬂammatory cytokines and expression of CD��L. Also the resident APC population 
probably has an immunomodulatory role.⁸⁴ – ⁸⁶
Chapter � 
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Table 1. Chromosomal aberrations and possible oncogenic mechanisms in GCB and ABC 
subtypes
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�.�.�. Primary testicular DLBCL
Epidemiology
Primary testicular lymphoma (PTL) is a rare disease, accounting for only �% of all non-
Hodgkin lymphomas and �% of testicular neoplasms. PTL encompasses Burki� lymphoma, 
follicular lymphoma and lymphoblastic lymphoma but the most frequent type is DLBCL 
(�� – ��%). Testicular DLBCL occurs predominantly in males older than �� years. There are 
currently no well established predisposing factors for testicular DLBCL.⁸⁷ – ⁹⁰
Clinical presentation
Testicular DLBCL present as a painless unilateral or in rare occasions bilateral testicular 
mass.⁸⁷ The most common diagnostic procedure is orchiectomy. The majority of cases present 
with Ann Arbor stage IE or IIE disease. Testicular DLBCL has a propensity to disseminate or 
relapse to other extranodal sites including the contralateral testis (in up to ��% of cases), CNS, 
skin, Waldeyer’s ring or lung.⁹¹
Prognosis and therapy
Prognosis is poor, with reported median survival rates of �� – �� months.⁹² Treatment 
usually consists of orchiectomy and systemic chemotherapy, with prophylactic scrotal radio-
therapy and CNS prophylaxis (high dose methotrexate and intrathecal chemotherapy). The 
relapse rate is high, between �� and ��%. Most relapses occur within � years of diagnosis, but 
relapses a�er as much as �� years have been reported.⁹¹�⁹³�⁹⁴
Microscopy and immunohistochemistry
Testicular DLBCL shows a diﬀuse growth pa�ern of large cells with pleomorphic nuclei. 
O�en the testicular parenchyma is completely obliterated but in some cases non-productive 
seminiferous tubules are present. Tumor-inﬁltrating T cells and macrophages may be seen.⁹²�⁹⁵ 
The immunophenotype is comparable to that of other nodal and extranodal DLBCL.⁹³ The 
proliferative index, as detected by Ki-��, ranges from �� – ��%.⁹⁶ Expression of Bcl� is frequent 
but not caused by a t(��;��)(q��;q��).⁹⁷ It is unknown whether testicular DLBCL correspond 
to the ABC or GCB subtype.
Molecular pathogenesis
Only a few studies of chromosomal aberrations or aberrant gene expression have been 
preformed in testicular DLBCL. Sequence analysis of immunoglobulin heavy chain (IgH) VDJ 
region in �� testicular DLBCL revealed a high frequency of somatic hypermutations and the 
presence of intraclonal IgH sequence variation, indicating a possible antigen-driven stimula-
tion, although it is unclear how this process can take place outside of the germinal center 
environment.⁹⁸ The frequent expression of anti-apoptotic factor Bcl� might be associated with 
the poor prognosis of testicular DLBCL, as it is in ABC-type nodal DLBCL. Another proposed 
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explanation for the aggressive behavior is the unique expression pa�ern of adhesion mole-
cules resulting in a lack of adhesion to the extracellular matrix.⁹⁹�¹⁰⁰ Recent studies have shown 
that testicular DLBCL very frequently lack expression of HLA class I and II proteins, o�en 
caused by hemi- and homozygous deletions in the HLA region at chromosome �p��.�, which 
could provide the lymphomas with a mechanism of immune escape.⁶⁹
�.�.�. Primary central nervous system DLBCL
Epidemiology
Primary CNS DLBCL represents less than �% of all non-Hodgkin lymphomas and � – �% 
of all brain tumors. The median age of presentation is approximately �� years, with a slight 
preponderance of male patients.¹⁰¹
Clinical presentation
Focal neurological deﬁcits are observed in �� – ��% of the patients. Neuropsychiatric symp-
toms (�� – ��%) and symptoms due to increased intracranial pressure are noticed. Nuclear 
magnetic resonance imaging (NMRI) is the most sensitive technique for tumor visualization. 
Approximately ��% of all CNS DLBCL are located supratentorially and in �� – ��% multiple 
lesions are present. Approximately ��% of patients develop intraocular lesions; dissemination 
to extraneural sites is very rare.
Prognosis and therapy
Prognosis used to be very poor but has been remarkably ameliorated by novel chemo-
therapeutic protocols. Polychemotherapy, including methotrexate as the most eﬃcient drug, 
has achieved a median overall survival of �� months. Autologous stem cell transplantation 
has been successfully applied in patients with recurrence and as salvage therapy in relapsing 
or refractory tumor. Radiotherapy is insuﬃcient to control the tumor and may, in combina-
tion with chemotherapy, result in severe adverse side-eﬀects such as leukoencephalopathy 
and cortical/subcortical atrophy. Most relapses aﬀect the CNS; systemic relapses relatively 
frequently involve the testis and breast.¹⁰²
Microscopy and immunohistochemistry
CNS DLBCL shows a diﬀuse intraparenchymal growth pa�ern of centroblast-like cells, 
sometimes forming perivascular cuﬀs. Tumor cells may be intermingled with reactive T cells, 
CD��-positive macrophages, activated microglial cells, and reactive astrocytes. Like in primary 
testicular DLBCL, expression of Bcl� is frequent but not associated with t(��;��)(q��;q��).¹⁰³ 
Only a few recent studies have reported on whether primary CNS DLBCL belong to the ABC 





Studies of IgH genes revealed a preferred usage of VH�-��, which is o�en detected in 
auto-immune disease. As in testicular DLBCL, a high frequency of somatic hypermutation 
of the VDJ genes and the presence of intraclonal variation suggests ongoing antigen-driven 
stimulation.¹⁰⁶ Aberrant hypermutation of other genes such as BCL�, PIM�, MYC, RhoH/TTF 
and Pax� has also been reported.¹⁰⁷ Expression or absence of chemokines and chemokine 
receptors or cytokines such as CXCL��, CXCL��¹⁰⁸ and IL-�¹⁰⁵ might contribute to the speciﬁc 
localization. Lack of expression of HLA class I and II proteins, o�en caused by the same �p��.� 
deletions as found in testicular DLBCL, might also allow CNS DLBCL to escape an immune 
a�ack.⁶⁹ Cytogenetic studies using ﬂuorescence in situ hybridization (FISH) or comparative 
genomic hybridization (CGH) are more frequent for CNS DLBCL than for testicular DLBCL. 
Similar to systemic DLBCL, approximately �� – ��% of CNS DLBCL have BCL� translocations 
but t(��;��)(q��;q��) and t(�;��)(q��;q��) are rare.¹⁰³ Common deletions are found at �q and 
gains at ��q, ��q and ��q��. Ampliﬁcation of ��q�� includes BCL� and MALT�, as has been 
described for extracerebral DLBCL of the ABC type as well.¹⁰⁹ Homozygous or hemizygous 
deletions at �p�� frequently aﬀect CDKN�A/p��.¹⁰³
�.� Scope of this thesis
The immune-privileged site-associated DLBCL (IP-DLBCL) of the testis and the CNS dif-
fer from their non-IP DLBCL counterpart in diﬀerent clinical and molecular aspects, but the 
most striking characteristic of IP-DLBCL is the lack of expression of HLA class I and II mol-
ecules, o�en associated with hemi- and homozygous deletions of the HLA region on chro-
mosome �p��.�. Because these deletions are such a hallmark event in IP-DLBCL we studied 
their signiﬁcance in relation to downregulation of gene expression by comparing global gene 
expression pa�erns between testicular DLBCL with and without deletions (C������ �). Since 
downregulation of HLA-DR gene expression was revealed as an important event in testicular 
DLBCL, independent from the mechanism that causes it, we also determined the eﬀect of this 
downregulation on global gene expression and T-cell inﬁltration.
In C������ � we used immunohistochemistry for CD��, Bcl� and MUM�, gene expression 
analysis and IgH somatic hypermutation analysis to investigate whether testicular DLBCL 
belong to the ABC or GCB subtype of DLBCL. We also proposed a change to the algorithm 




We had the unique opportunity to investigate a primary CNS DLBCL with an isolated 
relapse to the testis which occurred � years a�er initial diagnosis (C������ �). Based on the 
results of HLA protein expression, ABC/GCB typing and IgH somatic hypermutation analysis 
in this case and those presented in the previous chapters we propose a model for the develop-
ment of this lymphoma and IP-DLBCL in general.
It is known that diﬀerent subtypes of DLBCL such as ABC-type, GCB-type and CD�-posi-
tive DLBCL can be characterized by diﬀerent genomic aberrations, but not much is known 
about genetic aberrations in IP-DLBCL. In C������ � we investigated whether speciﬁc genomic 
aberrations are present in IP-DLBCL using array-CGH. We also determined the minimal com-
mon regions of gain and loss in DLBCL in general. Using a new, statistically robust technique 
we combined array-CGH data with global gene expression data to investigate which biologi-
cal pathways are deregulated by the genomic aberrations.
C������ � contains a general discussion centered on a model of IP-DLBCL lymphomagen-
esis in the context of immune privilege and immune escape, and recommendations for further 




�. Burnet M. Cancer - A biological approach. III. Viruses associated with neoplastic conditions. Br Med J 
����; �:��� – �.
�. Shankaran V, Ikeda H, Bruce AT, et al. IFNgamma and lymphocytes prevent primary tumour development and 
shape tumour immunogenicity. Nature ����; ���: ���� – ��.
�.  Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol ����; ��: ��� – ��.
�.  Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholan-
threne-induced ﬁbrosarcoma. Int Immunol ����; ��: ��� – ��.
�.  Kaplan DH, Shankaran V, Dighe AS, et al. Demonstration of an interferon gamma-dependent tumor surveillance 
system in immunocompetent mice. Proc Natl Acad Sci U S A ����; ��: ���� – ��.
�.  Bach EA, Aguet M, Schreiber RD. The IFN gamma receptor: a paradigm for cytokine receptor signaling. Annu 
Rev Immunol ����; ��: ��� – ��.
�.  Smyth MJ, Thia KYT, Street SEA, MacGregor D, Godfrey DI, Trapani JA. Perforin-mediated cytotoxicity is criti-
cal for surveillance of spontaneous lymphoma. J Exp Med ����; ���: ��� – ��.
�.  Takeda K, Hayakawa Y, Smyth MJ, et al. Involvement of tumor necrosis factor-related apoptosis-inducing ligand 
in surveillance of tumor metastasis by liver natural killer cells. Nat Med ����; �: �� – ���.
�.  Mori S, Jewe� A, Murakami-Mori K, Cavalcanti M, Bonavida B. The participation of the Fas-mediated cytotoxic 
pathway by natural killer cells is tumor-cell-dependent. Cancer Immunol Immunother ����; ��: ��� – ��.
��.  Zitvogel L, Terme M, Borg C, Trinchieri G. Dendritic cell-NK cell cross-talk: regulation and physiopathology. 
Curr Top Microbiol Immunol ����; ��� – ��.
��.  Boon T, van der Bruggen P. Human tumor antigens recognized by T lymphocytes. J Exp Med ����; ���: ��� – �.
��.  Rosenberg SA. A new era for cancer immunotherapy based on the genes that encode cancer antigens. Immunity 
����; ��: ��� – �.
��.  Weiss S, Bogen B. B-lymphoma cells process and present their endogenous immunoglobulin to major histocom-
patibility complex-restricted T cells. Proc Natl Acad Sci U S A ����; ��: ��� – �.
��.  Lauritzsen GF, Weiss S, Dembic Z, Bogen B. Naive idiotype-speciﬁc CD�+ T cells and immunosurveillance of 
B-cell tumors. Proc Natl Acad Sci U S A ����; ��: ���� – �.
��.  Gately MK, Wolitzky AG, Quinn PM, Chizzonite R. Regulation of human cytolytic lymphocyte responses by 
interleukin-��. Cell Immunol ����; ���: ��� – ��.
��.  Curtsinger JM, Valenzuela JO, Agarwal P, Lins D, Mescher MF. Type I IFNs provide a third signal to CD� T cells 
to stimulate clonal expansion and diﬀerentiation. J Immunol ����; ���: ���� – �.
��.  Mescher MF, Popescu FE, Gerner M, Hammerbeck CD, Curtsinger JM. Activation-induced non-responsiveness 
(anergy) limits CD� T cell responses to tumors. Semin Cancer Biol ����; ��: ��� – ���.
��.  Scha�ner EJ, Mascarenhas J, Bishop J, et al. CD�+ T-cell induction of Fas-mediated apoptosis in Burki�’s lym-
phoma B cells. Blood ����; ��: ���� – ��.
��.  Loeb LA. Mutator phenotype may be required for multistage carcinogenesis. Cancer Res ����; ��: ���� – �.
��.  Lengauer C, Kinzler KW, Vogelstein B. Genetic instabilities in human cancers. Nature ����; ���: ��� – �.
��.  Algarra I, Garcia-Lora A, Cabrera T, Ruiz-Cabello F, Garrido F. The selection of tumor variants with altered 
expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer 
Immunol Immunother ����; ��: ��� – ��.
��.  Bai XF, Liu J, Li O, Zheng P, Liu Y. Antigenic dri� as a mechanism for tumor evasion of destruction by cytolytic T 
lymphocytes. J Clin Invest ����; ���: ���� – ��.
��.  Rabinovich GA, Gabrilovich D, Sotomayor EM. Immunosuppressive strategies that are mediated by tumor cells. 
Annu Rev Immunol ����; ��: ��� – ��.
��.  Curiel TJ, Coukos G, Zou L, et al. Speciﬁc recruitment of regulatory T cells in ovarian carcinoma fosters immune 
privilege and predicts reduced survival. Nat Med ����; ��: ��� – �.
Introduction
26
��.  Wang RF, Peng G, Wang HY. Regulatory T cells and toll-like receptors in tumor immunity. Semin Immunol 
����; ��: ��� – ��.
��.  Kusmartsev S, Gabrilovich D. Role of immature myeloid cells in mechanisms of immune evasion in cancer. 
Cancer Immunol Immunother ����; ��: ��� – ��.
��.  Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. Macrophage polarization: tumor-associated macrophages 
as a paradigm for polarized M� mononuclear phagocytes. Trends Immunol ����; ��: ��� – ��.
��.  Takahashi H, Feuerhake F, Kutok JL, et al. FAS death domain deletions and cellular FADD-like interleukin �beta 
converting enzyme inhibitory protein (long) overexpression: alternative mechanisms for deregulating the extrin-
sic apoptotic pathway in diﬀuse large B-cell lymphoma subtypes. Clin Cancer Res ����; ��: ���� – ��.
��.  Scholl V, Stefanoﬀ CG, Hassan R, Spector N, Renault IZ. Mutations within the �’ region of FAS/CD�� gene in 
nodal diﬀuse large B-cell lymphoma. Leuk Lymphoma ����; ��: ��� – ��.
��.  Shin MS, Kim HS, Lee SH, et al. Mutations of tumor necrosis factor-related apoptosis-inducing ligand receptor � 
(TRAIL-R�) and receptor � (TRAIL-R�) genes in metastatic breast cancers. Cancer Res ����; ��: ���� – �.
��.  Soung YH, Lee JW, Kim SY, et al. Caspase-� gene is inactivated by somatic mutations in gastric carcinomas. 
Cancer Res ����; ��: ��� – ��.
��.  Kataoka T, Schroter M, Hahne M, et al. FLIP prevents apoptosis induced by death receptors but not by perforin/
granzyme B, chemotherapeutic drugs, and gamma irradiation. J Immunol ����; ���: ���� – ��.
��.  Weller M, Malipiero U, Aguzzi A, Reed JC, Fontana A. Protooncogene bcl-� gene transfer abrogates Fas/APO-
� antibody-mediated apoptosis of human malignant glioma cells and confers resistance to chemotherapeutic 
drugs and therapeutic irradiation. J Clin Invest ����; ��: ���� – ��.
��.  Iqbal J, Neppalli VT, Wright G, et al. BCL� expression is a prognostic marker for the activated B-cell-like type of 
diﬀuse large B-cell lymphoma. J Clin Oncol ����; ��: ��� – �.
��.  Hinz S, Trauzold A, Boenicke L, et al. Bcl-XL protects pancreatic adenocarcinoma cells against CD��- and 
TRAIL-receptor-mediated apoptosis. Oncogene ����; ��: ���� – ��.
��.  Medema JP, de Jong J, Peltenburg LTC, et al. Blockade of the granzyme B/perforin pathway through overexpres-
sion of the serine protease inhibitor PI-�/SPI-� constitutes a mechanism for immune escape by tumors. Proc Natl 
Acad Sci U S A ����; ��: ����� – ��.
��.  Ambrosini G, Adida C, Altieri DC. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. 
Nat Med ����; �: ��� – ��.
��.  Roth W, Isenmann S, Nakamura M, et al. Soluble decoy receptor � is expressed by malignant gliomas and sup-
presses CD�� ligand-induced apoptosis and chemotaxis. Cancer Res ����; ��: ���� – ��.
��.  Ziegler K, Unanue ER. Identiﬁcation of a macrophage antigen-processing event required for I- region-restricted 
antigen presentation to T lymphocytes. J Immunol ����; ���: ���� – ��.
��.  van den Elsen PJ, Holling TM, Kuipers HF, van der Stoep N. Transcriptional regulation of antigen presentation. 
Curr Opin Immunol ����; ��: �� – ��.
��.  Rock KL, Shen L. Cross-presentation: underlying mechanisms and role in immune surveillance. Immunol Rev 
����; ���: ��� – ��.
��.  Townsend AR, Rothbard J, Gotch FM, Bahadur G, Wraith D, McMichael AJ. The epitopes of inﬂuenza nucleopro-
tein recognized by cytotoxic T lymphocytes can be deﬁned with short synthetic peptides. Cell ����; ��: ��� – ��.
��.  O’Garra A, Arai N. The molecular basis of T helper � and T helper � cell diﬀerentiation. Trends Cell Biol 
����; ��: ��� – ��.
��.  Giuntoli RL II, Lu J, Kobayashi H, Kennedy R, Celis E. Direct costimulation of tumor-reactive CTL by helper T 
cells potentiate their proliferation, survival, and eﬀector function. Clin Cancer Res ����; �: ��� – ��.
��.  Ossendorp F, Mengede E, Camps M, Filius R, Melief CJ. Speciﬁc T helper cell requirement for optimal induc-
tion of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors. J Exp Med 
����; ���: ��� – ���.
��.  Groothuis TA, Griekspoor AC, Neĳssen JJ, Herberts CA, Nee�es JJ. MHC class I alleles and their exploration of 
the antigen-processing machinery. Immunol Rev ����; ���: �� – ��.
��.  Bryant P, Ploegh H. Class II MHC peptide loading by the professionals. Curr Opin Immunol ����; ��: �� – ���.
��.  Strawbridge AB, Blum JS. Autophagy in MHC class II antigen processing. Curr Opin Immunol ����; ��: �� – ��.
Chapter �
27
��.  van Ham M, van Lith M, Lillemeier B, et al. Modulation of the major histocompatibility complex class 
II-associated peptide repertoire by human histocompatibility leukocyte antigen (HLA)-DO. J Exp Med 
����; ���: ���� – ��.
��.  Alfonso C, Karlsson L. Nonclassical MHC class II molecules. Annu Rev Immunol ����; ��: ��� – ��.
��.  The MHC sequencing consortium. Complete sequence and gene map of a human major histocompatibility 
complex. Nature ����; ���: ��� – �.
��.  Piertney SB, Oliver MK. The evolutionary ecology of the major histocompatibility complex. Heredity 
����; ��: � – ��.
��.  Robinson J, Waller MJ, Parham P, et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the 
major histocompatibility complex. Nucl Acids Res ����; ��: ��� – �.
��.  Andersson G, Andersson L, Larhammar D, Rask L, Sigurdardo�ir S. Simplifying genetic locus assignment of 
HLA-DRB genes. Immunol Today ����; ��: �� – ��.
��.  Garcia-Lora A, Algarra I, Garrido F. MHC class I antigens, immune surveillance, and tumor immune escape. J 
Cell Physiol ����; ���: ��� – ��.
��.  Wang Z, Marincola FM, Rivoltini L, Parmiani G, Ferrone S. Selective histocompatibility leukocyte anti-
gen (HLA)-A� loss caused by aberrant pre-mRNA splicing in ���MEL�� melanoma cells. J Exp Med 
����; ���: ��� – ��.
��.  Koopman LA, Corver WE, van der Slik AR, Giphart MJ, Fleuren GJ. Multiple genetic alterations cause frequent 
and heterogeneous human histocompatibility leukocyte antigen class I loss in cervical cancer. J Exp Med 
����; ���: ��� – ��.
��.  Torres MJ, Ruiz-Cabello F, Skoudy A, et al. Loss of an HLA haplotype in pancreas cancer tissue and its corre-
sponding tumor derived cell line. Tissue Antigens ����; ��: ��� – ��.
��.  Bicknell DC, Rowan A, Bodmer WF. Beta�-microglobulin gene mutations: a study of established colorectal cell 
lines and fresh tumors. Proc Natl Acad Sci U S A ����; ��: ���� – �.
��.  Nie Y, Yang G, Song Y, et al. DNA hypermethylation is a mechanism for loss of expression of the HLA class I 
genes in human esophageal squamous cell carcinomas. Carcinogenesis ����; ��: ����.
��.  Dovhey SE, Ghosh NS, Wright KL. Loss of Interferon-gamma inducibility of TAP� and LMP� in a renal cell 
carcinoma cell line. Cancer Res ����; ��: ���� – ��.
��.  Seliger B, Ritz U, Abele R, et al. Immune escape of melanoma: ﬁrst evidence of structural alterations in two 
distinct components of the MHC class I antigen processing pathway. Cancer Res ����; ��: ���� – ��.
��.  Wagtmann N, Rajagopalan S, Winter CC, Peruui M, Long EO. Killer cell inhibitory receptors speciﬁc for HLA-C 
and HLA-B identiﬁed by direct binding and by functional transfer. Immunity ����; �: ��� – �.
��.  Lopez-Botet M, Perez-Villar JJ, Carretero M, et al. Structure and function of the CD�� C-type lectin receptor 
complex involved in recognition of HLA class I molecules. Immunol Rev ����; ���: ��� – ��.
��.  Karre K, Ljunggren HG, Piontek G, Kiessling R. Selective rejection of H-�-deﬁcient lymphoma variants suggests 
alternative immune defence strategy. Nature ����; ���: ��� – �.
��.  Ljunggren HG, Karre K. In search of the ‘missing self’: MHC molecules and NK cell recognition. Immunol 
Today ����; ��: ��� – ��.
��.  Yokoyama WM, Plougastel BFM. Immune functions encoded by the natural killer gene complex. Nat Rev Immu-
nol ����; �: ��� – ��.
��.  Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG�D and T-cell 
activation. Nature ����; ���: ��� – �.
��.  Riemersma SA, Jordanova ES, Schop RF, et al. Extensive genetic alterations of the HLA region, including 
homozygous deletions of HLA class II genes in B-cell lymphomas arising in immune- privileged sites. Blood 
����; ��: ���� – ��.
��.  Rimsza LM, Roberts RA, Campo E, et al. Loss of major histocompatibility class II expression in non-immune 
privileged site diﬀuse large B cell lymphoma is highly coordinated and not due to chromosomal deletions. 
Blood ����; ���: ���� – �.
��.  Sano H, Compton LJ, Shiomi N, Steinberg AD, Jackson RA, Sasaki T. Low expression of human histocompat-
ibility leukocyte antigen-DR is associated with hypermethylation of human histocompatibility leukocyte 
antigen-DR alpha gene regions in B cells from patients with systemic lupus erythematosus. J Clin Invest 
����; ��: ���� – ��.
Introduction
28
��.  Jaﬀe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization classiﬁcation of tumours: pathol-
ogy and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press;  ����.
��.  The International Non-Hodgkin’s Lymphoma Prognostic Factors Project. A predictive model for aggressive non-
Hodgkin’s lymphoma. N Engl J Med ����; ���: ��� – ��.
��.  Ng AK. Diﬀuse Large B-Cell Lymphoma. Semin Radiat Oncol ����; ��: ��� – ��.
��.  Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diﬀuse large B-cell lymphoma identiﬁed by gene 
expression proﬁling. Nature ����; ���: ��� – ��.
��.  Hans CP, Weisenburger DD, Greiner TC, et al. Conﬁrmation of the molecular classiﬁcation of diﬀuse large B-cell 
lymphoma by immunohistochemistry using a tissue microarray. Blood ����; ���: ��� – ��.
��.  Chang CC, McClintock S, Cleveland RP, et al. Immunohistochemical expression pa�erns of germinal center 
and activation B-cell markers correlate with prognosis in diﬀuse large B-cell lymphoma. Am J Surg Pathol 
����; ��: ��� – ��.
��.  Morgensztern D, Martin MG, Lossos IS. Gene expression proﬁling in diﬀuse large B-cell lymphoma. Leuk Lym-
phoma ����; ��: ��� – ��.
��.  Davis RE, Brown KD, Siebenlist U, Staudt LM. Constitutive nuclear factor kappaB activity is required for sur-
vival of activated B cell-like diﬀuse large B cell lymphoma cells. J Exp Med ����; ���: ���� – ��.
��.  Lossos IS, Morgensztern D. Prognostic biomarkers in diﬀuse large B-cell lymphoma. J Clin Oncol 
����; ��: ��� – ����.
��.  Miller TP, Lippman SM, Spier CM, Slymen DJ, Grogan TM. HLA-DR (Ia) immune phenotype predicts outcome 
for patients with diﬀuse large cell lymphoma. J Clin Invest ����; ��: ��� – �.
��.  Rimsza LM, Roberts RA, Miller TP, et al. Loss of MHC class II gene and protein expression in diﬀuse large B-cell 
lymphoma is related to decreased tumor immunosurveillance and poor patient survival regardless of other 
prognostic factors: a follow-up study from the Leukemia and Lymphoma Molecular Proﬁling Project. Blood 
����; ���: ���� – �.
��.  Medawar PB. Immunity to homologous gra�ed skin. III. The fate of skin homogra�s transplanted to the brain, 
to subcutaneous tissue, and to the anterior chamber of the eye. Br J Exp Pathol ����; ��: �� – ��.
��.  Carson MJ, Doose JM, Melchior B, Schmid CD, Ploix CC. CNS immune privilege: hiding in plain sight. Immunol 
Rev ����; ���: �� – ��.
��.  Fĳak M, Meinhardt A. The testis in immune privilege. Immunol Rev ����; ���: �� – ��.
��.  Niederkorn JY. See no evil, hear no evil, do no evil: the lessons of immune privilege. Nat Immunol ����; �: ��� – �.
��.  Moller MB, d’Amore F, Christensen BE. Testicular lymphoma: a population-based study of incidence, clinico-
pathological correlations and prognosis. Eur J Cancer ����; ��: ���� – �.
��.  Shahab N, Doll DC. Testicular lymphoma. Semin Oncol ����; ��: ��� – ��.
��.  Doll DC, Weiss RB. Malignant lymphoma of the testis. Am J Med ����; ��: ��� – ��.
��.  Zucca E, Roggero E, Bertoni F, Cavalli F. Primary extranodal non-Hodgkin’s lymphomas. Part �: Gastrointestinal, 
cutaneous and genitourinary lymphomas. Ann Oncol ����; �: ��� – ��.
��.  Fonseca R, Habermann TM, Colgan JP, et al. Testicular lymphoma is associated with a high incidence of extra-
nodal recurrence. Cancer ����; ��: ��� – ��.
��.  Al-Abbadi MA, Ha�ab EM, Tarawneh M, Orazi A, Ulbright TM. Primary testicular and paratesticular lym-
phoma: a retrospective clinicopathologic study of �� cases with emphasis on diﬀerential diagnosis. Arch Pathol 
Lab Med ����; ���: ���� – �.
��.  Vitolo U, Ferreri AJ M, Zucca E. Primary testicular lymphoma. Crit Rev Oncol Hematol ����; ��: ��� – �.
��.  Zucca E, Conconi A, Mughal TI, et al. Pa�erns of outcome and prognostic factors in primary large-cell 
lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 
����; ��: �� – �.
��.  Miedler JD, MacLennan GT. Primary testicular lymphoma. J Urol ����; ���: ����.
��.  Al-Abbadi MA, Ha�ab EM, Tarawneh MS, Amr SS, Orazi A, Ulbright TM. Primary testicular diﬀuse large 
B-cell lymphoma belongs to the nongerminal center B-cell-like subgroup: A study of �� cases. Mod Pathol 
����; ��: ���� – �.
Chapter �
29
��.  Lambrechts AC, Looĳenga LH, van ’t Veer MB, van Echten J, Timens W, Oosterhuis JW. Lymphomas with 
testicular localisation show a consistent BCL-� expression without a translocation (��;��): a molecular and 
immunohistochemical study. Br J Cancer ����; ��: �� – �.
��.  Hyland J, Lasota J, Jasinski M, Petersen RO, Nordling S, Mie�inen M. Molecular pathological analysis of testicu-
lar diﬀuse large cell lymphomas. Hum Pathol ����; ��: ���� – �.
��.  Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood ����; ��: ���� – ��.
���. Horstmann WG, Timens W. Lack of adhesion molecules in testicular diﬀuse centroblastic and immunoblastic B 
cell lymphomas as a contributory factor in malignant behaviour. Virchows Archiv ����; ���: �� – ��.
���.  Cote TR, Manns A, Hardy CR, Yellin FJ, Hartge P, AIDS/Cancer Study Group. Epidemiology of brain lymphoma 
among people with or without acquired immunodeﬁciency syndrome. J Natl Cancer Inst ����; ��: ��� – �.
���.  Jahnke K, Thiel E, Martus P, et al. Relapse of primary central nervous system lymphoma: clinical features, out-
come and prognostic factors. J Neurooncol ����; ��: ��� – ��.
���.  Cobbers JM, Wolter M, Reifenberger J, et al. Frequent inactivation of CDKN�A and rare mutation of TP�� in 
PCNSL. Brain Pathol ����; �: ��� – ��.
���.  Camilleri-Broet S, Criniere E, Broet P, et al. A uniform activated B-cell-like immunophenotype might explain the 
poor prognosis of primary central nervous system lymphomas: Analysis of �� cases. Blood ����; ���: ��� – �.
���.  Rubenstein J, Fridlyand J, Shen A, et al. Gene expression and angiotropism in primary CNS lymphoma. Blood 
����; ���: ���� – ��.
���.  Montesinos-Rongen M, Kuppers R, Schluter D, et al. Primary central nervous system lymphomas are 
derived from germinal-center B cells and show a preferential usage of the V�-�� gene segment. Am J Pathol 
����; ���: ���� – ��.
���.  Montesinos-Rongen M, Van Roost D, Schaller C, Wiestler OD, Deckert M. Primary diﬀuse large B-cell lympho-
mas of the central nervous system are targeted by aberrant somatic hypermutation. Blood ����; ���: ���� – ��.
���.  Smith JR, Braziel RM, Paole�i S, Lipp M, Uguccioni M, Rosenbaum JT. Expression of B-cell-a�racting chemokine 
� (CXCL��) by malignant lymphocytes and vascular endothelium in primary central nervous system lymphoma. 
Blood ����; ���: ��� – ��.
���.  Weber T, Weber RG, Kaulich K, et al. Characteristic chromosomal imbalances in primary central nervous system 





Mechanisms and eﬀects of loss of 
human leukocyte antigen class II expression 
in immune-privileged site-associated 
B-cell lymphoma
Marĳe Booman, Jenny Douwes, Annuska M. Glas, Sietske A. 
Riemersma, Ekaterina S. Jordanova, Klaas Kok, Andreas Rosenwald, 
Daphne de Jong, Ed Schuuring and Philip M. Kluin
Published in Clinical Cancer Research ����; ��:���� – ����
32
Abstract
Loss of human leukocyte antigen (HLA) expression on tumor cells is frequent in diﬀuse 
large B-cell lymphoma (DLBCL) arising in immune-privileged sites, such as the testis and 
central nervous system, and is associated with small homozygous deletions of HLA-DQ/
HLA-DR and larger hemizygous deletions of the major histocompatibility complex (MHC) 
region. To be�er understand the signiﬁcance of downregulation of HLA class II expression in 
relation to the homozygous and hemizygous deletions, we analyzed global gene expression 
pa�erns in a series of �� testicular DLBCL a�er characterization of these deletions.
Low levels of HLA-DR mRNA in whole testicular DLBCL samples were associated with a 
strong downregulation of numerous immune-related genes speciﬁc for T cells, macrophages, 
antigen presentation and processing, lymphocyte activation, chemokines and chemokine 
receptors, and the complement system. The number of CD�-positive tumor-inﬁltrating T cells 
was also signiﬁcantly lower in low expressors of HLA-DR mRNA. Interestingly, hemizygous 
and homozygous deletions in the MHC region did not have any additional eﬀect on global 
gene expression.
In conclusion, we found that loss of HLA class II mRNA expression in testicular DLBCL is 
associated with a signiﬁcant change in global gene expression pa�erns. This eﬀect is indepen-





Diﬀuse large B-cell lymphomas (DLBCL) are a heterogeneous group of non-Hodgkin lym-
phomas, of which ��% present at extranodal sites. Many extranodal DLBCL behave clinically 
essentially diﬀerent from nodal DLBCL. A subset of extranodal DLBCL arises in immune-
privileged sites (IP-DLBCL), such as the central nervous system (CNS) or the testis. Among 
the extranodal DLBCL, testicular DLBCL stand out with a characteristic high relapse rate to 
the CNS and contralateral testis¹ and a very poor prognosis. In addition, patients with a low-
risk International Prognostic Index have a very poor outcome.²
We previously described the loss of human leukocyte antigen (HLA) class I and II expres-
sion on tumor cells in more than ��% of the primary IP-DLBCL of the testis and CNS.³ – ⁶ 
In both IP-DLBCL subtypes small homozygous deletions aﬀected the HLA-DR and HLA-
DQ genes, whereas larger hemizygous deletions aﬀected the whole major histocompatibility 
complex (MHC) region, including class I and III regions, as well. The speciﬁcity of this down-
regulation in testicular DLBCL was conﬁrmed in a recent immunohistochemical study on a 
large series of primary extranodal DLBCL presenting at various sites.⁷ In another recent study 
on predominantly primary nodal (non-IP) DLBCL, Rimsza et al.⁸ showed that loss of expres-
sion of HLA class II is highly discriminative for the clinical behavior of the disease and by far 
the most signiﬁcant single prognostic factor. Furthermore, loss of HLA-DR expression cor-
related with a low number of CD�-positive T cells, suggesting that a presumed loss of tumor 
surveillance may have a negative eﬀect on patient outcome.
To be�er understand the signiﬁcance of downregulation of HLA class II expression in 
relation to the homozygous and hemizygous deletions, we studied a series of primary tes-
ticular DLBCL by gene expression microarray analysis a�er detailed characterization of the 
hemizygous and homozygous deletions. Additionally, we studied the gene expression pat-
terns in testicular DLBCL with low and high HLA-DR mRNA expression. Here, we show that 
compared with normal B cells and primary nodal DLBCL, HLA-DR and HLA-DQ expression 
is dramatically downregulated in most testicular lymphomas. Whereas neither homozygous 
nor hemizygous deletions have any major additional eﬀect on overall gene expression sig-
natures, downregulation of HLA-DR is associated with a strong reduction of expression of 
many immune-associated genes and the number of inﬁltrating T cells.
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Materials and methods
Tissue sample collection and selection
Frozen and paraﬃn-embedded lymphoma samples from �� primary testicular DLBCL and 
�� primary nodal DLBCL according to the REAL and WHO classiﬁcations⁹�¹⁰ were collected 
from the tissue banks at the University Medical Center Groningen, Leiden University Medical 
Center, Joseﬁne Ne�ens Institute, Ro�erdam (courtesy Dr. L. Looĳenga), and Netherlands 
Cancer Institute, Amsterdam, The Netherlands. All patients were immunocompetent, and 
patients with testicular DLBCL had stage IE or IIE disease. Seven of �� testicular DLBCL (see 
T���� �) have been characterized previously by ﬂuorescence in situ hybridization (FISH) and 
immunohistochemistry³ and were included because of the presence of deletions. The median 
percentage of tumor cells present in frozen tissue sections as assessed on H&E-stained slides 
was ��%, with two testicular DLBCL cases having a tumor percentage less than ��%.
Immunohistochemistry
Paraﬃn or frozen tissue sections were stained with mouse monoclonal antibodies against 
HLA-A/G and HLA-B/C (HCA� and HC��, respectively; kindly provided by Dr. J. Nee�es, 
NKI, Amsterdam, The Netherlands; ref. ��) and against HLA-DR (LN�; Biotest AG, Drei-
eich, Germany). For staining of paraﬃn sections, standard microwave/citrate buﬀer (pH �.�) 
antigen retrieval was performed. Routine hyperplastic tonsil samples were used as positive 
controls. Cases were considered negative when the staining of the tumor cells was completely 
absent in the presence of a positive internal control of macrophages, endothelial cells and/or 
T cells.
Detection and quantiﬁcation of T cells was performed as described previously.⁷ In brief, 
sections were stained with polyclonal anti-CD� (A����; DAKO, Copenhagen, Denmark) and 
monoclonal anti-granzyme B (��F�; Sanbio, Uden, The Netherlands). The number of CD�-
positive and granzyme B-positive lymphocytes was quantiﬁed using a video overlay-based 
measuring system (Q-PRODIT; Leica, Cambridge, UK) and expressed as the number of posi-
tive cells per � mm² of tumor.
Interphase FISH
Nuclei were isolated from frozen tissue sections and centrifuged onto glass slides. A cen-
tromeric � probe (D�Z�; Oncor, Gaithersburg, MD, USA) was labeled with biotin-��-dUTP 
(Roche, Basel, Switzerland) by standard nick translation and cohybridized with locus-speciﬁc 
probes, which were labeled with digoxygenin-�� dUTP (Roche). These included PAC ��N�� 
(RCPI-� library) for HLA-DQA and DRB (class II), cosmid M��A (American Tissue Culture 
Center) for tumor necrosis factor alpha (class III), and cosmids C���K���� and C���B���� 
(Imperial Cancer Research Fund chromosome � library) for HLA-A (class I). Hybridization 
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and immunodetection were performed as previously described.¹² In each DLBCL, signals 
were counted in ��� nuclei. As a control, each probe combination was hybridized on nuclei 
from � routine hyperplastic tonsil samples. Cutoﬀ levels for the detection of hemizygous or 
homozygous loss were determined as the average percentage of nuclei harboring a deletion 
in these � tonsil samples plus thrice the SD. Cutoﬀ levels for the presence of hemizygous dele-
tions of MHC class I, III and II probes were thus set at ��%, ��% and ��% of nuclei harboring 
a deletion, respectively. Cutoﬀ levels for homozygous deletions ranged from �% – �%.
Chromosome � array comparative genomic hybridization and data analysis
The chromosome � comparative genomic hybridization (CGH) array contained ��� 
genomic clones mapping to chromosome �, which were selected from the �-Mb BAC collec-
tion obtained from Dr. N. Carter (Wellcome Trust Sanger Institute, UK; ref. ��), the Human 
BAC Resource Consortium_� Set (Dr. P. de Jong, Children’s Hospital Oakland Research Insti-
tute, USA), and the RPCI-� PAC library. In addition, the array contained ��� clones selected 
from a subtelomere array.¹⁴ Detailed information on the clone set of this array is available in 
S������������ T���� S�.
Genomic DNA was isolated from frozen tissue sections using the high salt method 
a�er overnight SDS/proteinase K digestion. Labeling and hybridization were performed as 
previously described.¹⁴ DLBCL DNA was cohybridized with a standard reference consisting 
of a pool of either �� normal male or �� normal female genomic DNA samples. Data extrac-
tion, normalization and analysis were performed as described previously.¹⁴
cDNA microarray hybridization
RNA isolation, linear ampliﬁcation and hybridization of ��K cDNA microarrays were per-
formed as described previously.¹⁵�¹⁶ Detailed protocols can also be found at h�p://www.nki.nl/
nkidep/pa/microarray/protocols.htm. Microarray slides containing over ��,��� cDNA clones 
from the Research Genetics Human Sequence Veriﬁed library were prepared at the central 
microarray facility of the Netherlands Cancer Institute. Detailed information on the clone 
set can be found at h�p://microarray.nki.nl/download/geneid.html. These arrays were chosen 
for reasons of availability and their coverage of the MHC region. Twenty-six testicular and 
�� nodal DLBCL samples were each cohybridized with a standard reference of pooled and 
ampliﬁed total RNA from ﬁve hyperplastic tonsils acquired by routine tonsillectomy. Each 
hybridization was repeated as a dye reversal. Ten percent of the experiments consisted of self-
self hybridizations of the standard reference as a control for the experimental variation.
Fluorescent signals were extracted from the arrays by a DNA Microarray Scanner (Agilent, 
Palo Alto, CA, USA) and quantiﬁed using Imagene �.� so�ware (Biodiscovery, El Segundo, CA, 
USA). The resulting data were normalized and corrected for various biases according to Yang 
et al.¹⁷ Ratios of expression in DLBCL compared with tonsil were calculated and weighted 
averages and conﬁdence levels were calculated according to the Rose�a error model.¹⁸ Based 
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on MA plots and the results from the error model, spots with an average intensity measure-
ment A less than � over all experiments were excluded from further analysis due to the fact 
that ratio measurements from those spots show too large a variation to be reliable.
Gene expression data analysis
Unsupervised clustering of genes and lymphoma samples was performed using hierar-
chical clustering in Genesis.¹⁹ Using the Pearson correlation coeﬃcient or Euclidian distance, 
complete similarity metrics were calculated based on expression levels in all tumors or in all 
genes for clustering of genes and experiments, respectively. Supervised clustering was per-
formed using Signiﬁcance Analysis of Microarrays (SAM).²⁰ The median false discovery rate 
was used as a measure of signiﬁcance. The results of supervised clustering were visualized 
using Genesis. Sca�erplots of mean and median gene expression levels of diﬀerent DLBCL 
groups were constructed in R (R Foundation for Statistical Computing, Vienna, Austria). 
Additional t statistics for selected genes were calculated using Welch’s t test and visualized 
in sca�erplots using Prism � (GraphPad So�ware, Inc., San Diego, CA, USA). Functional 
relationships and signal transduction pathways that involve selected genes were analyzed in 
Pathway Assist version �.� (Iobion Labs, La Jolla, CA, USA). 
Results
HLA expression and deletions in the HLA region
Primary testicular and primary nodal DLBCL were characterized for HLA protein expres-
sion on the tumor cells and for genomic deletions of the MHC region by interphase FISH. 
Results are summarized in T���� �. Loss of expression of HLA-A/G and HLA-DR together 
with a high frequency of hemizygous and/or homozygous deletions in testicular DLBCL³ was 
conﬁrmed in this extended series.
To determine the boundaries of the hemizygous deletions that o�en extend beyond the 
MHC region more in detail, �� testicular DLBCL for which genomic DNA was available were 
hybridized to a chromosome �-speciﬁc CGH array (T���� �). F����� � shows the clone density 
of the array for chromosome � and the deletions found in the MHC region in � of these �� 
cases, including � cases with a proven deletion as determined by interphase FISH. All but one 
of these � cases harbored an extensive hemizygous deletion of the MHC region. Additionally, 
in case ��T a small homozygous deletion could be distinguished. Mapping of the hemizygous 
deletions showed a highly variable length towards the telomere �p; in � of the � cases, it did 
not extend further than �.� Mb telomeric of the MHC class I region. Most interestingly, at the 
centromeric side all larger deletions ended in a region of � Mb between two BAC clones (RP�-
���B� and RP�-���A��) located �.� and �.� Mb centromeric of the MHC class II region.
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Comparison of expression of genes located in the MHC region between nodal and testicular DLBCL
Testicular and nodal DLBCL were hybridized on ��k cDNA microarrays to compare their 
global gene expression proﬁles. SAM analysis using a false discovery rate (FDR) of less than 
�.�� resulted in ��� diﬀerently expressed clones, of which ��� were signiﬁcantly higher (fold 
change between �.� and �.�) and ��� were signiﬁcantly lower (fold change between �.� and 
�.�) expressed in testicular than in nodal DLBCL. Of these lower expressed clones, � repre-
sented HLA class II genes: HLA-DQB (� clone), HLA-DRB (� clones) and HLA-DOA (� clone). 
Hierarchical clustering of the samples and genes in Genesis assigned the � HLA class II clones 
to one cluster, indicating coregulation (F����� �).
To separately investigate expression variations of other genes in the MHC region, in 
the absence of the dominant inﬂuence of the classical and non-classical HLA class I and II 
genes, an unsupervised cluster analysis was performed using all non-HLA clones from the 
MHC region that were present on the array (n = ��� clones). These genes are not diﬀerentially 
expressed in testicular and nodal DLBCL (data not shown).
�p deletions have a limited eﬀect on global gene expression proﬁles of testicular DLBCL
We analyzed eﬀects of the hemizygous �p deletions involving the MHC region on global 
gene expression in testicular DLBCL. To that end we selected � cases without any deletions 
(�T, �T, ��T, ��T and ��T) and � cases with large hemizygous deletions in a high percentage 
of nuclei (�T, �T, �T, �T, �T and ��T) as determined by interphase FISH. There was no further 
selection based on HLA protein or mRNA expression. Within the la�er group, all cases had 
deletions in the MHC class II and III regions, and � of � had additional deletions of the class 
I region (T���� �). Although no signiﬁcant diﬀerences between these two groups were found 
in a supervised clustering analysis using SAM, it is noteworthy that � of the �� low expressed 
genes selected at a minimum FDR of ��% are located at chromosome �p, including � at �p��.�: 
DEK (�p��.�), GNL�, TUBB, DOM�Z (�p��.�) and SLC��B� (�p��.�).
We separately analyzed the possible eﬀects of the small homozygous deletions on gene 
expression of the involved HLA genes and possible downstream targets. Five testicular 
DLBCL with a homozygous deletion in a high percentage of nuclei (�T, �T, �T, �T and ��T) 
were chosen to compare to � cases without any deletions (�T, �T, ��T, ��T, and ��T), again 
with no further selection for HLA protein or mRNA expression level. The mean gene expres-
sion values for each group were visualized in a sca�erplot (F����� �), illustrating that the two 
groups are highly similar. No signiﬁcant diﬀerences in gene expression between both groups 
were found with SAM (data not shown). Expression of classical HLA class II genes in both 
the deletion-positive and deletion-negative testicular DLBCL groups was � to � times lower 
than in the reference tonsil sample, conﬁrming downregulation of these genes irrespective of 
deletions. There is a trend for the HLA-DQ and HLA-DR genes towards an even lower expres-
sion in cases with a homozygous deletion. Expression levels of non-classical HLA genes were 
equal to that in the reference tonsil sample. 
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Figure 2. Supervised cluster analysis of testicular and nodal DLBCL
Top panel: Supervised cluster analysis of testicular (orange) and nodal (blue) DLBCL resulted in 431 clones that are diﬀerentially 
expressed. In the right margin the cluster containing HLA class II genes is indicated. Presence of deletions and HLA-DR protein 
expression are included at the top for each case. FISH results: +: deletion present; ±: deletion of borderline signiﬁcance (see 
Table 1); -: no deletion; Extended hemi: hemizygous deletion of MHC class I, II and II regions; Class II homo: homozygous dele-
tion of HLA class II. HLA-DR protein expression (in tumor cells, determined by immunohistochemistry): +: protein present; -: 
protein absent.
Bottom panel: HLA class II cluster enlarged. Individual HLA class II clones are indicated in the right margin.
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Global gene expression in relation to downregulation of HLA-DR mRNA expression
We analyzed global gene expression changes in testicular DLBCL in relation to HLA-DR 
mRNA expression (measured by averaging ratios of ﬁve HLA-DR clones). Six testicular lym-
phomas had expression levels similar to that of the tonsillar lymphoid tissue (ratio between 
�.�� and �.��), the other �� had lower expression levels varying from �.� to �.� times lower 
than the tonsillar reference sample (T���� �). Of note, all � cases without a deletion had a low 
expression. In a supervised analysis using SAM the global gene expression proﬁles of the � 
cases with the highest HLA-DR mRNA expression levels (�T, ��T, ��T, ��T, ��T and ��T) were 
compared with the proﬁles of the � cases with the lowest HLA-DR mRNA expression levels 
(�T, �T, �T, �T, ��T and ��T). Three hundred thirty-two clones were signiﬁcantly (FDR≤�.���) 
downregulated in the la�er (this list is available as S������������ T���� S�). The gene list 
was analyzed using Pathway Assist �.� and the Entrez Gene database (National Center for 
Biotechnology Information), which identiﬁed a large number of immune response-related 
genes, including macrophage and T-cell markers, costimulatory molecules and chemokines. 
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Figure 3. HLA class II gene expression in testicular DLBCL with and without homozygous 
deletions
For each gene the average log ratio in testicular DLBCL with homozygous deletions of HLA-DQ/HLA-DR genes (2T, 4T, 6T, 8T 
and 19T) is plotted against the average log ratio in testicular DLBCL without deletions (10T, 7T, 1T, 8T, 5T and 4T). Solid lines: 
equal expression level; dotted lines: two-fold diﬀerence. Big black dots: non-classical HLA class II genes; black stars: classical 
HLA class II genes.
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That is, of the ��� unique genes and expressed sequence tags that are encoded by the ��� 
clones, �� (��%) were immune related. T���� � summarizes the most important ﬁndings. Of 
note, we found no signiﬁcant correlation between HLA-DR mRNA and CD�� and/or CD�� 
mRNA expression, indicating that the diﬀerences are unlikely caused by diﬀerences in tumor 
content in these samples (T���� �A).
Because the previous results imply that the downregulation of expression of HLA-DR is 
a dominant phenomenon in many testicular DLBCL, we also intended to compare testicu-
lar DLBCL with and without HLA-DR protein expression on the tumor cells as assessed by 
immunohistochemistry. However, because only � cases were scored as positive, this analysis 
could not be performed.
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* Genes included in host response signature published by Monti et al;21
† Genes included in lymph node signature published by Rosenwald et al.22
Table 2. Immune response genes that are downregulated in testicular DLBCL with low HLA-
DR mRNA expression
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Correlation between HLA-DR mRNA levels and immune signatures
Subsequently, we investigated the relation between HLA-DR mRNA expression and 
immune-mediated responses as measured by other gene expression studies in nodal DLBCL. 
Monti et al.²¹ have distinguished � types of nodal DLBCL, of which one is characterized by a 
high expression of so-called ‘host response’ genes and a large number of inﬁltrating inﬂam-
matory and immune cells. The Staudt group has deﬁned a ‘lymph node signature’ in nodal 
DLBCL, of which a selection of genes was associated with good prognosis.²²�²³ We compared 
these two signatures with our own set of genes that are downregulated in low expressors of 
HLA-DR mRNA. Fi�y-two of �� genes from the ‘host response signature’ were present on our 
array, of which �� were downregulated in testicular DLBCL with low HLA-DR mRNA expres-
sion. One hundred sixteen of ��� genes from the ‘lymph node signature’ were present on the 
array, of which �� were downregulated. The genes with a direct immunological function are 
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A. Cell surface markers (mRNA gene expression; average logratio ± SD)
HLA-DR high HLA-DR low p value*
HLA-DR -0.06 ± 0.08 -2.33 ± 0.12 <0.0001
B cell
CD19 -0.36 ± 0.15 -0.13 ± 0.17 NS
CD22 -0.54 ± 0.10 -0.43 ± 0.13 NS
T cell
CD4 0.51 ± 0.13 -0.86 ± 0.17 0.0001
CD8A 0.11 ± 0.03 -0.31 ± 0.03 <0.0001
TCRα -0.17 ± 0.11 -1.85 ± 0.25 0.0008
TCRβ -0.29 ± 0.14 -1.53 ± 0.27 0.0044
Macrophage
CD68 1.21 ± 0.18 -0.11 ± 0.15 0.0004
CD14 -0.07 ± 0.04 0.12 ± 0.06 0.0042
Natural killer cell
KLRG1 0.94 ± 0.11 -0.08 ± 0.12 0.0001
B. T-cell content (immunohistochemistry; average number of cells/mm2
HLA-DR high HLA-DR low p value*
CD3+ cells 2299 ± 194 818 ± 187 0.0030
Granzyme B+ cells 982 ± 326 553 ± 227 NS
* p-values determined using Welch’s t test.  
ns: not signiﬁcant.
Table 3. Diﬀerential expression of cell surface markers and T-cell content in testicular DLBCL 
with high and low HLA-DR mRNA levels
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indicated in T���� �. Only � genes tended towards a higher expression in cases with low HLA-
DR mRNA expression: CD�� (T���� �A), cystatin C and granulysin. Finally, the ��� genes 
from the ‘lymph node signature’ were able to discern testicular DLBCL with high or low levels 
of HLA-DR expression in a hierarchical cluster analysis (data not shown).
To investigate if the number of inﬁltrating T cells is related to the apparent downregula-
tion of the immune response, we compared numbers of CD�-positive T cells and granzyme 
B-positive cells between � testicular DLBCL with high HLA-DR mRNA expression (cases �T, 
��T, ��T and ��T) and � with low HLA-DR mRNA expression (cases �T, �T, �T and �T) using 
Welch’s t test. These cases were included in the study by Riemersma et al.⁷ Cases with low 
expression contained a signiﬁcantly lower number of T cells, but there was no diﬀerence in 
the total number of granzyme B-positive activated cytotoxic T cells and natural killer cells 
(T���� �B).
Discussion 
Recent gene expression studies have suggested that downregulation of HLA class II 
expression has a major biological eﬀect reﬂected in clinical tumor characteristics and outcome. 
This has been shown for B-cell lymphomas, that naturally express HLA class II on lymphoma 
cells,⁸�²² but also for carcinomas in which HLA class II can be expressed on the antigen-
presenting cells (APC) within the tumor.²⁴. It is increasingly appreciated that not only HLA 
class I but also class II is essential for mounting an adequate anti-tumor immune response. 
Antigen presentation via HLA class II is indispensable to activate a CD�-positive T-cell popu-
lation that may induce a CD�-positive T cell-mediated cytotoxic anti-tumor response²⁵�²⁶ and 
recruit additional eﬀector cell populations, such as macrophages.²⁶�²⁷
In carcinomas an immune-mediated anti-tumor response is mainly mediated by profes-
sional APCs. In B-cell lymphomas both professional APCs as well as the tumor B cells may 
play an active role in the anti-tumor response by cytotoxic T cells, whereas the tumor cells 
might also be dependent on T helper cells and/or tumor promoting factors produced by 
macrophages. This generates a complex and intimate immunological relationship between 
tumor cells and surrounding reactive cells. The signiﬁcance of this immunological context 
of DLBCL has recently been underlined by gene expression studies with the identiﬁcation 
of a ‘host response signature’ and ‘lymph node signature’ in these lymphomas.²¹�²² Although 
these phenomena might be tightly linked to the expression of HLA class II on the tumor cells 
and/or APCs, this has not been studied extensively. Our data show that the loss of expression 
of HLA-DR at the mRNA level in whole testicular DLBCL samples is associated with a signiﬁ-
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cantly lower expression of many immune-related genes. Detailed analysis revealed numerous 
genes involved in diﬀerent aspects of the immune response, including markers for T cells, 
natural killer cells, macrophages and APCs (T���� �). The coordinate downregulation of these 
genes with HLA-DR levels indicates a severe disruption of the immune response in testicular 
DLBCL with low HLA-DR mRNA expression levels. Fi�y percent of the HLA-DR coregulated 
genes with an immune function in our study overlap with the ‘host response’ and ‘lymph 
node’ signatures published by other groups,²¹�²² supporting the relevance of this ﬁnding.
To conﬁrm our data on a diﬀerent platform, we independently analyzed � of the testicular 
DLBCL with the lowest and � of the cases with the highest HLA-DR mRNA expression levels 
on the Aﬀymetrix U��� �.� Plus array. We again found a downregulation of genes involved 
in immune recognition in the low expressors. Sixty-eight of the ��� diﬀerentially expressed 
genes (��%) had an immune-related function, of which �� were already identiﬁed in cDNA 
array analysis (M Booman and A Rosenwald, unpublished results).
Intriguingly, in studies published by Shipp et al.²¹�²⁸ HLA class II gene expression levels 
were neither associated with clinical outcome nor with their ‘host response proﬁle’. This 
could possibly be a�ributed to technical dissimilarities: whereas we and the LLMPP group 
used cDNA arrays that gave consistent results for multiple clones of the same HLA class II 
genes, Monti et al.²¹ used Aﬀymetrix oligo arrays, and in the supplementary data set pub-
lished with their article diﬀerent probe sets for the same HLA class II genes were not consis-
tently assigned to one expression signature. This might be due to the fact that most Aﬀymetrix 
probe sets for HLA class II genes, indicated by _x_at, “may cross-hybridize in an unpredict-
able manner” (ref. ��, p. ��).
Using immunohistochemistry on a subset of our cases, a low level of HLA-DR mRNA 
expression was associated with a signiﬁcantly lower number of inﬁltrating CD�-positive cells 
and a slightly lower number of granzyme B-positive cells (T���� �B). This is in concordance 
with the low levels of TCRα and TCRβ mRNA in these cases as assessed by microarray analy-
sis (T���� �A) and indicates that the low expression of immune response-associated genes can 
partly be a�ributed to a lower number of inﬁltrating T cells. In a recent investigation on ��� 
DLBCL, including �� HLA-DR protein-positive and �� negative testicular DLBCL, no signiﬁ-
cant correlation between HLA-DR protein expression on the tumor cells and the numbers of 
inﬁltrating T cells was found.⁷ These seemingly contradictory data suggest that a concerted 
downregulation of HLA-DR on both the tumor cells and surrounding APCs, and not HLA 
expression on only the tumor cells, is essential in debilitating the immune response. Because 
we could study gene expression in only � cases with retained HLA class II protein expression 
on the tumor cells, we could not further explore this issue on the gene expression level.
Several macrophage- and monocyte-related genes, including CD��, were downregulated 
in testicular DLBCL with low HLA class II mRNA levels. Intriguingly, CD�� showed upregu-
lation in this group (T���� �A). In Burki� lymphoma, CD�� is known to be involved in IL-��-
induced phagocytosis of apoptotic material and has an anti-inﬂammatory eﬀect. Moreover, 
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CD��-positive macrophages produce BAFF to inhibit apoptosis of tumor cells.³⁰ The proper-
ties of these tumor-inﬁltrating macrophages are reminiscent of polarized M� macrophages.³¹ 
We hypothesize that increased CD�� levels in macrophages in testicular DLBCL with low 
HLA-DR mRNA expression might promote lymphoma growth and survival and thus might 
be related to the poor prognosis associated with HLA class II-negative DLBCL. This possible 
tumor survival mechanism remains to be elucidated in testicular DLBCL.
In many IP-DLBCL arising at immune-privileged sites, such as the testis and CNS, but also 
in a minority of nodal (non-IP) DLBCL, downregulation of HLA class II is eﬀected by hemi-
zygous and homozygous deletions and/or mitotic recombination at chromosome �p��.�.³�⁴ 
Using interphase and DNA ﬁber FISH, we previously showed that the small homozygous 
deletions only involve the HLA-DQ and HLA-DR genes.³ Gene expression analysis now indi-
cates that expression of HLA class II mRNA is very low in testicular DLBCL in general and 
that the small homozygous deletions result only in a slightly further downregulation. The 
mechanism by which HLA class II downregulation is accomplished in testicular DLBCL with-
out homozygous deletions remains to be elucidated. Very recently Rimsza et al. reported that 
in non-IP DLBCL loss of HLA class II mRNA expression is not due to chromosomal dele-
tions but rather correlates with loss of expression of MHC class II transactivator and invariant 
chain genes, indicating loss of transcriptional activation.³² We explored this for our testicular 
DLBCL without homozygous deletions. Indeed, there was a signiﬁcant correlation between 
expression of MHC class II transactivator and HLA class II genes in all �� testicular DLBCL 
without a homozygous deletion (r ranges from �.�� for HLA-DQ to �.�� for HLA-DR using 
the Spearman correlation), whereas this correlation was absent in the �� cases with a signiﬁ-
cant homozygous deletion. These results conﬁrm that multiple mechanisms are involved in 
the downregulation of HLA class II genes in DLBCL. The intriguing question why so many 
IP-DLBCL use a deletion instead of transcriptional downregulation remains to be answered. 
Perhaps the tumor cells of IP-DLBCL are more dependent on a shutdown of the immune 
response and therefore need a more permanent loss of HLA class II expression as mediated 
by physical deletion of the HLA class II-encoding genes.
Hemizygous deletions are much larger than the homozygous deletions and may target 
many other genes than the classical HLA genes at chromosome �p. Array-CGH analysis 
showed that the minimal region of interest on chromosome �p is restricted to a region of �.� 
Mb starting �.� Mb telomeric of MHC class I and extending � Mb centromeric of MHC class 
II. Global gene expression pa�erns showed a very limited eﬀect of the hemizygous deletions, 
suggesting that no speciﬁc genes in this region are targeted.
Previous studies on predominantly nodal DLBCL have shown that loss of expression of 
HLA class II is an independent adverse prognostic factor.⁸ The present series of testicular 
DLBCL is not suitable for a meaningful correlative study on the relationship between HLA 
class II expression and clinical behavior because the cases were collected over a very long 
period of time and treatment was highly variable.
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In conclusion, we found that loss of HLA class II mRNA expression in lymphoma cells and 
the surrounding inﬁltrate is associated with a signiﬁcant change in global gene expression 
pa�erns reﬂecting a decrease in the immune response, which is paralleled by a decrease in 
the relative number of inﬁltrating reactive T cells. This eﬀect is independent of the mechanism 
causing the downregulation of HLA-DR on the lymphoma cells.
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Abstract
Diﬀuse large B-cell lymphomas (DLBCL) constitute a heterogeneous group of lymphomas 
in which germinal center B cell-like and activated B cell-like subtypes can be discerned based 
on pathology, clinical presentation and gene expression pa�erns. Testicular DLBCL form an 
immune-privileged site-related subgroup of DLBCL with an unfavorable prognosis.
In the present study cDNA microarray analysis, immunohistochemistry for CD��, Bcl� 
and MUM�, and somatic hypermutation analysis of the immunoglobulin heavy chain gene 
rearrangements were used to determine the subtype of primary testicular DLBCL. Immuno-
histochemistry revealed �� of �� testicular DLBCL with an activated B cell-like immunopheno-
type and � of �� with an ambiguous immunophenotype co-expressing CD�� and high levels 
of MUM�. cDNA microarray analysis of these �� and � additional cases showed a uniform 
activated B cell-like gene expression pa�ern for both immunophenotypes. Somatic hypermu-
tation analysis of immunoglobulin heavy chain genes showed a very high mutation load in � 
cases tested, but intraclonal heterogeneity was found at low level in only one of these cases.
It is concluded that primary testicular DLBCL have uniform activated B cell-like subtype 




Microarray analysis of diﬀuse large B-cell lymphoma (DLBCL) resulted in the identiﬁ-
cation of � subgroups: one with germinal center B cell-like features (GCB), associated with 
a favorable prognosis; one with an activated B cell-like expression pa�ern (ABC); and one 
with a more undetermined ‘type �’ pa�ern.¹ – ³ Immunohistochemistry is commonly used as 
an alternative for microarray analysis: CD�� and Bcl� for a germinal center phenotype and 
MUM� (IRF�) for an activated phenotype. Several studies have tested these markers, some 
showing that this classiﬁcation has prognostic signiﬁcance.⁴ – ⁹ In the single study in which 
microarray analysis was directly compared with immunohistochemistry, results were concor-
dant in ��% of GCB and ��% of ABC cases.⁴
Somatic hypermutation (SHM) of immunoglobulin heavy chain (IgH) genes is frequent 
in both DLBCL subtypes and is indicative of passage through the germinal center.¹⁰ How-
ever, intraclonal heterogeneity indicating ongoing SHM is found more frequently in the GCB 
subtype.¹¹ Although expression of activation-induced deaminase (AID) is indispensable for 
SHM,¹² there appears to be no relationship with ongoing SHM in DLBCL.¹³ – ¹⁵
A subset of DLBCL arises at immune-privileged sites such as the testis and the central 
nervous system (CNS). Testicular DLBCL show a striking propensity to disseminate to the 
CNS¹⁶ and both share a poor prognosis.¹⁷�¹⁸ To investigate the nature of testicular DLBCL, we 
determined the subtype by immunohistochemistry and gene expression proﬁling. Addition-
ally, the IgH mutation frequency and intraclonal heterogeneity, as well as AID expression, 
were analyzed.
Materials and Methods
Tissue sample collection and selection
Frozen samples from �� primary testicular and�� primary nodal DLBCL were collected 
from the tissue banks at the UMCG; Leiden University Medical Center, Leiden (Dr. P.M. 
Jansen); Joseﬁne Ne�ens Institute, Ro�erdam (Dr L. Looĳenga); and Netherlands Cancer 
Institute, Amsterdam (The Netherlands). The tumor cell percentage was assessed on H&E-
stained slides, � testicular DLBCL cases having a tumor percentage less than ��%. These � 
cases had similar global gene expression pa�erns to cases with higher tumor cell percentages 
and therefore were not excluded from the study. Additional paraﬃn-embedded material was 
available for � of �� nodal and �� of �� testicular DLBCL cases. The collection and analysis of 
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�� DLBCL transformed from follicular lymphoma (FL) have been described previously;¹⁹ only 
gene expression data from these cases were included. This study was conducted following 
institutional ethical guidelines.
Immunohistochemistry
Immunohistochemistry was performed on �� testicular and � nodal DLBCL for which 
paraﬃn material was available. Sections were stained with antibodies against Bcl� (PG-B�p; 
DAKO, Glostrup, Denmark), CD�� (��C�; Novocastra, Newcastle upon Tyne, UK) and MUM� 
(MUM�p; DAKO). A�er antigen retrieval, staining was performed on the Ventana Nexus IHC 
staining module (Ventana, Tucson, AZ, USA). Cases were considered positive if more than 
��% of neoplastic cells were stained.⁴ Cases expressing CD�� and/or Bcl� but not MUM� were 
assigned to the GCB subtype, MUM�+ CD��- cases to the ABC subtype, and MUM�+ CD��- 
cases to an ‘ambiguous’ subtype.
cDNA microarray hybridization
RNA isolation from frozen tissue, linear RNA ampliﬁcation and hybridization of ��K 
cDNA microarrays were performed as described previously¹⁹�²⁰ (see also h�p://www.nki.nl/
nkidep/pa/microarray/protocols.htm). Microarray slides containing more than ��,��� cDNA 
clones from the Research Genetics Human Sequence Veriﬁed Library were prepared at the 
central microarray facility of the Netherlands Cancer Institute (for information on the clone 
set see h�p://microarry.nki.nl/download/geneid.html). Twenty-six testicular and �� nodal 
DLBCL were each co-hybridized with a standard reference of ampliﬁed, pooled RNA from � 
hyperplastic tonsils. Each hybridization was repeated as a dye reversal.
Fluorescent signals were extracted by a DNA Microarray Scanner (Agilent, Palo Alto, CA, 
USA) and quantiﬁed using Imagene �.� (Biodiscovery, El Segundo, CA, USA). Data were nor-
malized and corrected according to Yang et al.²¹ Ratios of expression in DLBCL compared 
with tonsil were calculated, and weighted averages and conﬁdence levels were calculated 
according to the Rose�a error model.²² Based on ratio-intensity (M-A) plots and results from 
the error model, spots with an average intensity measurement A (�.� �log (cy� x cy�)) lower 
than � over all experiments were excluded from further analysis. Microarray data were depos-
ited in the GEO database under accession number GSE����.
Cluster analysis
DLBCL were clustered using a published ABC/GCB proﬁle²³ in Genesis.²⁴ This ��-gene 
proﬁle was chosen because it discriminated best between ABC and GCB cases in cross-plat-
form analysis. Twenty-one of the �� genes are represented on the cDNA microarray used. 
Statistical signiﬁcance was assigned to this clustering using LPS score analysis²³ with a cut-
oﬀ of �.��. Alternatively, samples were clustered using a larger set of ��� genes that were 
discriminative (t test, p≤�.������) between ABC and GCB cases¹ (data provided by Dr. A. 
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Rosenwald). A�er median centering of the expression data over all samples, complete simi-
larity metrics were calculated using the Pearson correlation coeﬃcient. Expression data of 
�� DLBCL transformed from FL were included in this analysis. Supervised clustering was 
performed using Signiﬁcance Analysis of Microarrays (SAM),²⁵ with a false discovery rate 
(FDR) cut-oﬀ of �.��.
Somatic hypermutation analysis
Genomic DNA was isolated from frozen tissue using high salt a�er overnight SDS/
proteinase K digestion. IGH DNA was ampliﬁed by multiplex PCR using FR�/JH primers.²⁶ 
�-FAM labeled products were analyzed on a MegaBACE ���� using Genetic Proﬁler �.� so�-
ware (GE Healthcare, UK). In all cases a clonal band was detected; for � cases showing one 
(n = �) or two (n = �) prominent bands without a polyclonal B-cell background, the FR�/JH 
PCR was repeated using unlabeled primers. Puriﬁed PCR products were cloned into the 
PCR�.�-TOPO vector using the TOPO TA cloning kit (Invitrogen, Breda, The Netherlands). 
From each case �� colonies (�� for each duplicate PCR) were subjected to an M�� PCR. A�er 
puriﬁcation, PCR products were sequenced. Tumor sequences were compared with germline 
VH sequences using IMGT/VQUEST.²⁷ Sequences were aligned using ClustalW.²⁸ Intraclonal 
heterogeneity was deﬁned by the presence of at least � mutation in at least � PCR sequences, 
preferably from � separate PCR reactions; unconﬁrmed heterogeneity by a mutation in only 
one of the PCR sequences.²⁹
To detect aberrant somatic hypermutation of PAX� and MYC, PCR products were cloned 
and analyzed as previously described.³⁰
Quantitative RT-PCR for AID
From �� testicular DLBCL enough material was available for cDNA synthesis using the 
SuperScriptII system (Invitrogen). Taqman quantitative RT-PCR (qRT-PCR) was performed 
as previously described³¹ using the Assay-On-Demand kit for AID (Applied Biosystems) and 
TBP as an endogenous control. Three reactive tonsils were used as a calibrator. Expression 
factor diﬀerences were calculated as previously described.³¹
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Results
Immunohistochemical analysis of �� testicular DLBCL for CD��, Bcl� and MUM� expres-
sion (T���� � ��� F����� �) revealed two subtypes: a MUM�+ CD��- ABC subtype (n = ��), and 
a MUM�+ CD��+ ambiguous subtype (n = �). In all cases except case �, MUM� was expressed 
in more than ��% of the tumor cells. Bcl� was expressed in � of �� ABC and � of � ambiguous 
cases. Five nodal DLBCL were of the GCB and � of the ABC type.
To investigate how gene expression proﬁling would classify especially the ambiguous-
type DLBCL, we clustered �� testicular DLBCL together with �� nodal DLBCL according to an 
ABC/GCB proﬁle of �� genes,²³ �� of which are represented on our microarray. Since none of 
the testicular DLBCL had a GCB immunophenotype, we included DLBCL transformed from 
FL as GCB subtype controls to balance the clustering. Hierarchical cluster analysis resulted 
in distinct ABC and GCB subtype clusters (F����� �). A ‘type �’ cluster, characterized by low 
expression of both ABC and GCB genes, was absent. Twenty-three of the �� DLBCL trans-
formed from FL clustered in the GCB group whereas the �� nodal DLBCL were divided over 
GCB (n = �) and ABC proﬁles (n = �). One of � nodal DLBCL for which an immunophenotype 
was determined (case F) showed a discrepancy between immunohistochemistry and array 
analysis. Twenty-ﬁve of �� testicular DLBCL clustered in the ABC group. The single excep-
tional GCB case (case �) had an ambiguous immunophenotype. This case showed the lowest 
MUM� protein expression of all testicular DLBCL (��% tumor cells positive). All other tes-
ticular DLBCL with an ambiguous immunophenotype clustered with the ABC-like cases. LPS 
score analysis conﬁrmed the clustering results (T���� � ��� F����� �): � cases were unclassi-
ﬁed (� also being ambiguous by IHC); only case �, also with an ambiguous immunopheno-
type, showed a discrepancy with clustering.
Next, all cases were clustered according to a larger set of ��� genes that were discrimi-
native (t test, p ≤ �.������) in the study of Alizadeh et al.¹ The results were similar to those 
using the ��-gene set, including the classiﬁcation of cases � and F as GCB subtypes (data not 
shown).
Since the ambiguous-type testicular DLBCL did not diﬀer from the ABC subtype, we per-
formed a third analysis in which we used all ��,��� clones on the array in a SAM analysis to 
determine whether any other genes were diﬀerentially expressed. No signiﬁcant diﬀerences 
were found, conﬁrming the similarity of ambiguous-type and ABC-like testicular DLBCL. 
In view of the unusual CD�� protein expression in cases with an ABC gene expression pro-
ﬁle, we investigated whether CD�� protein and mRNA expression were correlated. Although 
there were some exceptions, the Spearman rank test showed a signiﬁcant correlation between 
protein and mRNA expression (data not shown).
Since previous results suggested that the presence of ongoing SHM of IGH genes is indica-
tive of a GCB phenotype,¹¹ we analyzed SHM levels and ongoing SHM in � evaluable cases 
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(T����� � ��� �). In case ��, two clones were detected (��a and ��b). With the exception of ��a, 
all cases showed a very high level of mutations compared with germline (��.� – ��.�%, aver-
age ��.�%). Intraclonal variation was present in case � only, showing an ambiguous immuno-
phenotype and an ABC-type gene expression proﬁle. In this case, � major groups of �� and � 
sequences that diﬀered for � nucleotides were detected. Single sequences within each group 
contained additional unconﬁrmed mutations. The other � lymphomas contained a low num-
ber of mutations in single sequences only, which were not considered as intraclonal varia-
tion.
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Figure 1. Immunostaining for CD10 and MUM1 in cases with ambiguous immunophenotype
(a) Positive staining of CD10 (case 4). (b) Detail of CD10 staining (case 1). (c) Positive staining of MUM1 (case 4). (d) Detail of 
MUM1 staining (case 1). Panels a and b illustrate that in cases with an ambiguous phenotype, CD10 is expressed on the tumor 










1 11T + + + ambiguous ABC 1.00 17.4¤ 9.71
2 9T + + + ambiguous ABC 1.00 ND 6.47
3 1T + + + ambiguous ABC 1.00 ND 4.74
4 5T + + + ambiguous GCB 0.00 ND 2.42
5 17T + + + ambiguous ABC 0.82 ND ND
6 24T + + + ambiguous ABC 0.79 ND ND
7 25T + + + ambiguous ABC 1.00 ND ND
8 23T + – + ambiguous ABC 0.01 ND ND
9 2T – + + ABC ABC 0.99 11.0 5.66
10 19T – + + ABC ABC 1.00 16.2 0.86
11 7T – – + ABC ABC 1.00 16.7 0.14
12 3T – + + ABC ABC 1.00 23.3/2.3 5.47
13 20T – – + ABC ABC 1.00 23.3 2.71
14 12T – + + ABC ABC 1.00 ND 0.24
15 18T – – + ABC ABC 1.00 ND 1.27
16 14T – – + ABC ABC 0.99 ND 1.72
17 8T – + + ABC ABC 1.00 ND 2.15
18 16T – + + ABC ABC 1.00 ND 3.12
19 4T – ND + ABC ABC 1.00 ND 7.29
20 6T – + + ABC ABC 0.46 ND ND
21 13T – + + ABC ABC 1.00 ND ND
22 15T – – + ABC ABC 1.00 ND ND
23 22T ND ND ND ND ABC 1.00 18.0 1.03
24 26T ND ND ND ND ABC 1.00 ND 1.45
25 10T ND ND ND ND ABC 1.00 ND ND
26 21T ND ND ND ND ABC 1.00 ND ND
Nodal DLBCL
A 4N + + – GCB GCB 0.00 ND ND
B 7N + + – GCB GCB 0.00 ND ND
C 2N + + – GCB GCB 0.00 ND ND
D 5N + + – GCB GCB 0.00 ND ND
E 8N – + – GCB GCB 0.00 ND ND
F 3N – + + ABC GCB 0.00 ND ND
G 9N – – + ABC ABC 0.99 ND ND
H 1N – – + ABC ABC 1.00 ND ND
I 10N ND ND ND ND ABC 1.00 ND ND
J 6N ND ND ND ND ABC 1.00 ND ND
Table 1. Results from cDNA microarray, immunohistochemistry, SHM analysis and qRT-PCR
*UPN: Unique patient number, used for cross-reference to GEO database and Booman et al.37 
† LPS score p values: >0.90 = ABC, <0.10 = GCB, 0.10-0.90 = unclassiﬁed. 
‡ Somatic hypermutation load of tumor VH genes indicated as percentage of mutations compared with the germline VH 
sequence (see also Table 2). 
§ AID gene expression levels indicated relative to levels in reactive hyperplastic tonsil. 
¤ This case showed intraclonal variation 
ND: not determined.
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Figure 2. Hierarchical clustering of testicular DLBCL according to a 21-gene ABC/GCB 
expression proﬁle
Genes are color-coded: orange: GCB-associated genes, blue: ABC-associated genes. Samples are color-coded: green: testicular 
DLBCL, blue: nodal DLBCL, red: transformed follicular DLBCL. Results from immunohistochemical classiﬁcation and LPS score 
analysis are indicated at the top (red marks indicate discrepancies between analyses): IHC: G = GCB, A = ABC, circle = ambigu-
ous; LPS: G = GCB, A = ABC, star = unclassiﬁed. LPS p values for unclassiﬁed cases (from left to right): 0.46, 0.82, 0.79 and 0.80 
(see Table 1).
Intraclonal heterogeneity
Case № VH gene % mutations* PCR sequences Conﬁrmed† Unconﬁrmed†
9 3-72 11.0 16 0 1
10 3-7 16.2 19 0 4
11 3-21 16.7 18 0 1
1 4-59 17.4 20 4‡ 8
23 3-23 18.0 19 0 1
13 4-34 23.3 19 0 1
12 clone a 4-34 23.3 8 0 3
12 clone b 4-34 2.3 6 0 1
Table 2. Mutation analysis of immunoglobulin gene V regions
* Percentage of mutations in the consensus sequence compared with the germline sequence. CDR3 sequences were excluded 
from calculations.
† Total number of nucleotide variations. Conﬁrmed mutations were found in more than one PCR sequence, unconﬁrmed muta-
tions were found in single sequences only.
‡ One mutation leads to a stop codon in FR2.
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Because AID is indispensable for SHM and in view of the high mutation levels of tes-
ticular DLBCL, we performed qRT-PCR for AID on �� cases. AID expression was extremely 
variable but did not correlate with SHM (T���� �); however, the single testicular DLBCL with 
intraclonal heterogeneity had the highest AID expression. Insuﬃcient cases were analyzed to 
determine whether AID expression diﬀered between the ABC and ambiguous immunophe-
notypes.
Discussion
We demonstrate that testicular DLBCL has an almost exclusive ABC type of gene expres-
sion, while one-third of the same lymphomas show an ambiguous protein expression pa�ern 
with strong co-expression of both germinal center and activated B-cell markers. Based on 
cDNA expression analysis using either �� well-deﬁned genes or a larger list of ��� genes, all 
ambiguous-type cases were classiﬁed as ABC-like DLBCL. Furthermore, supervised cluster 
analysis using the expression data of all ��,��� clones on the microarray did not reveal any 
signiﬁcant diﬀerences between cases with an ambiguous or activated protein proﬁle. We were 
therefore not able to explain the (up)regulation of CD�� expression in the ambiguous-type 
cases, nor could we identify any downstream genes that were (de)regulated upon expression 
of CD��. The ambiguous-type cases express high levels of ABC-related genes and are essen-
tially diﬀerent from ‘type �’ DLBCL that express low levels of both ABC- and GCB-associated 
genes.²
We explored the relationship between our ambiguous subtype and previously published 
subtypes of DLBCL. Algorithms to determine DLBCL subtype diﬀer mostly in the assignment 
of CD��+ MUM�+ cases. Hans et al. assigned all CD��-positive cases to the GCB subtype, 
regardless of MUM� expression.⁴ Their GCB subtype had a be�er overall survival than the 
ABC subtype. Other studies using this algorithm either conﬁrmed this association⁹ or found 
no association.⁸ Colomo et al. used a diﬀerent algorithm, classifying CD��+ MUM�+ cases as 
‘other’, and found no association with prognosis.⁵ Chang et al. used an algorithm comparable 
to that of Hans et al. but classiﬁed cases with simultaneous expression of a germinal center 
and an activation marker as ‘activated GCB’.⁶ ‘Activated GCB’ cases and ABC cases had a simi-
lar worse overall survival. These literature data combined with our expression data suggest 
that both our ambiguous cases and the ‘activated GCB’ cases of Chang et al. could be be�er 
classiﬁed as (a variant of) the ABC subtype of DLBCL. Interestingly, the gene that was most 
uniformly expressed at the RNA level in both our ambiguous and ABC cases is FOXP�, which 
is associated with signiﬁcantly worse overall survival and a non-GCB phenotype.³²�³³
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There is only one other report on expression of CD��, Bcl� and MUM� in testicular 
DLBCL.³⁴ Using the Hans algorithm, Hasselblom et al. identiﬁed �� of �� ABC and � of �� 
GCB cases; there was no diﬀerence in overall survival. Reclassifying these cases with our 
algorithm, �� of �� were ABC-, � of �� ambiguous- and � of �� GCB-type DLBCL. It would be 
interesting to investigate if this reclassiﬁcation improves the association with overall survival. 
Unfortunately, our series of testicular DLBCL was not suitable for a meaningful study on the 
relation between subtype and prognosis, because cases were collected over a very long period 
of time and treatment was highly variable.
DLBCL of the testis has many biological and clinical characteristics in common with pri-
mary DLBCL of the CNS. Both expand in immune-privileged sites and have a relatively poor 
prognosis¹⁷�¹⁸ and testicular DLBCL very frequently disseminate to the CNS.¹⁶ They share 
an unusual phenotype with frequent loss of HLA class I and class II expression, which is 
o�en associated with homo- and hemizygous deletions at chromosome �p.³⁵ – ³⁷ Moreover, 
they have a very high frequency of �q deletions³⁸�³⁹ and express Bcl� protein but lack BCL� 
breakpoints.⁴⁰�⁴¹ A recent study showed that most primary DLBCL of the CNS have an ABC 
immunophenotype⁴² and, similar to our data, almost all cases had a high expression of 
MUM�. However, in contrast to our testicular DLBCL cases, only � of �� cases were positive 
for CD��.
To conﬁrm further the ABC subtype of testicular DLBCL, we analyzed IgH gene SHM and 
intraclonal heterogeneity. The levels of SHM exceeded not only those found in normal non-
neoplastic GC and post-GC B cells (�.� – �.�%), but also those in FL (average ��,�%),⁴³ as well 
as those in large series of non-immune-privileged site-associated DLBCL.²⁹�⁴⁴ Similar high 
SHM levels were found in a series of �� testicular DLBCL⁴⁵ and in DLBCL of the CNS.⁴⁶ – ⁴⁸ 
In DLBCL, SHM also aﬀects genes such as BCL�, PIM�, MYC, Rho/TTF and PAX�.³⁰�⁴⁹ We 
therefore performed a mutation analysis of PAX� and MYC in � of the testicular DLBCL cases 
already analyzed for SHM of IGH genes. Mutations were found in PAX� (� of � cases) and 
MYC (� of � cases), conﬁrming the data in other DLBCL, in particular DLBCL of the CNS. 
Mutations were also present in protein coding domains and in some instances led to changes 
in individual amino acids (data not shown).
Intraclonal heterogeneity is more pronounced in GCB- than in ABC-type DLBCL, with 
respect to both the percentage of tumors aﬀected and the load of mutations per tumor.¹¹ This 
intraclonal heterogeneity may be the consequence of ongoing or prior diversiﬁcation by SHM. 
Since SHM is almost restricted to the germinal center, it would be surprising to ﬁnd many 
ongoing mutations in testicular DLBCL. Of note, DLBCL of the testis is not related to the very 
rare subtype of follicular lymphoma of the testis, which is mainly seen in pediatric patients 
or adolescents.⁵⁰ – ⁵² In our series of testicular DLBCL only one case showed intraclonal hetero-
geneity, and the number of ongoing mutations was relatively low in comparison to the total 
number of mutations. In a previous study on SHM,⁴⁵ intraclonal heterogeneity was reported 
in all �� testicular DLBCL. The discrepancy between the two studies might lie in the deﬁnition 
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of ongoing SHM. Hyland et al. gave no details on the mutations in each case, but the single 
illustrated case contained only single unique nucleotide changes in single sequences, which 
are not regarded as ongoing SHM using the criteria of Lossos et al.²⁹
In view of our data, we speculate that the founder cell of each testicular DLBCL may have 
originated from a B-cell population that underwent high-level SHM before entering the testis. 
Lymphoma cells undergoing SHM can become immunogenic due to immunoglobulin idiot-
ype changes or replacement mutations in coding domains of proteins such as PAX� and MYC. 
Therefore, tumor cells with very high levels of mutations might only be allowed to survive 
and expand in immune-privileged sites such as the testis and CNS, whereas they would have 
been killed at other sites. A�er disruption of the blood-testis or blood-brain barrier by the 
growing tumor and the inﬂux of cytotoxic cells, immune escape might be further facilitated 
by downregulation of HLA class I and II molecules, which is a prominent feature of these 
DLBCL of the testis and CNS.³⁵ – ³⁷
Since SHM is mediated by AID and the mutation levels in our testicular DLBCL were 
very high, we analyzed AID mRNA expression by qRT-PCR (AID was not represented on 
the microarray). Expression levels were comparable to those of other DLBCL¹⁴�¹⁵�⁵³ and were 
not associated with SHM, although the single case with intraclonal heterogeneity had the 
highest AID expression. Pasqualucci et al.¹⁴ showed that most AID protein is localized in 
the cytoplasm of both normal and neoplastic B cells, whereas the function of AID should be 
exerted in the nucleus. Therefore, the amount of AID molecules measured by cDNA analysis 
and immunohistochemistry might not directly correlate to the actual rate of (ongoing) SHM. 
Human AID expression is regulated by stimulatory and inhibitory factors such as PAX�,⁵⁴ E-
proteins,⁵⁵ IL-�,⁵⁶ Id�⁵⁴ and Id�,⁵⁵ many also known to regulate B-cell activity. Pasqualucci et 
al.¹⁴ indeed showed that AID expression is higher in ABC than in GCB DLBCL. Interestingly, 
IL-� itself is positively regulated by MUM�.⁵⁷ In line with these results, we found a positive 
correlation between MUM� (microarray) and AID (qRT-PCR) expression (data not shown).
In conclusion, primary testicular DLBCL have a uniform ABC-like gene expression pat-
tern, although some cases have an ambiguous immunophenotype. The high levels of SHM 
but low levels of intraclonal heterogeneity support this interpretation. Our ﬁndings also indi-
cate that speciﬁc subtypes of DLBCL may have expression pa�erns that deviate from those 
of DLBCL in general, and that the current immunohistochemical algorithms may not be fully 
applicable on such cases.
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Abstract
We describe a patient with a primary diﬀuse large B-cell lymphoma of the central ner-
vous system who developed a localized testicular relapse a�er � years. Both tumors lacked 
HLA-DR expression, the relapse additionally lost HLA class I expression. Immunoglobulin 
heavy chain gene rearrangements were identical in both lymphomas with extensive and 
ongoing somatic hypermutations resulting in extensive idiotype modulation. We hypothesize 
that these immune sanctuaries initially provided a ‘safe haven’ for the tumor cells. When 
the environment becomes more permissive for an anti-tumor response, the continuous idio-





Primary lymphoma of the testis and the central nervous system (CNS) are rare forms of 
diﬀuse large B-cell lymphoma (DLBCL). Both lymphoma types are immune-privileged site-
associated DLBCL (IP-DLBCL), are EBV-negative (except for immune-compromised patients), 
and almost exclusively have an activated B cell-like (ABC) phenotype.¹�² Lymphomas are 
considered to develop and progress in a multistep manner due to accumulation of genetic 
aberrations. Where a lymphoma is subject to selective pressure of the immune system, such 
aberrations may give rise to an ‘immune escape’ phenotype.³ A common aberration leading 
to immune escape of DLBCL of the testis and the CNS is loss of HLA expression.⁴�⁵�⁶ Another 
common feature of both lymphoma types is a high level of (o�en ongoing) somatic hypermu-
tation (SHM) in the immunoglobulin heavy chain (IgH) genes.¹�⁷�⁸
Although usually presenting with stage IE disease, patients with DLBCL of the testis or 
the CNS have a poor prognosis that has only recently improved upon introduction of novel 
chemotherapy strategies.⁹�¹⁰ Primary testicular DLBCL frequently relapse in the CNS up to 
�� years a�er initial presentation.¹⁰�¹¹ Relapse of CNS DLBCL is almost always (�� – ��%) con-
ﬁned to the CNS. One patient has been reported with a relapse of CNS DLBCL in the testis, 
accompanied by extensive systemic involvement,¹² but no patients have been described with 
a relapse solely in the testis.
We describe a unique patient having a CNS DLBCL with a relapse conﬁned to the testis � 
years a�er diagnosis. The ongoing modulation of the idiotype, in addition to progressive loss 




Formalin-ﬁxed paraﬃn-embedded material of both CNS and testicular lymphomas was 
available. Staining with anti-CD�� (L��; DAKO, Glostrup, Denmark) conﬁrmed the B-cell 
origin. Stainings with anti-CD� (PS�; Monosan, Uden, The Netherlands), anti-CD� (C�/���B; 
DAKO) and anti-CD�� (PG-M�; DAKO) were performed to determine the presence of T cells 
and macrophages in the tumor microenvironment. Stainings with anti-Bcl� (PG-B�p; DAKO), 
anti-CD�� (��C�; Novocastra, Newcastle upon Tyne, UK) and anti-MUM� (MUM�p; DAKO) 
were considered positive if more than ��% of neoplastic cells were stained. Stainings with 
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anti-HLA-A/G, anti-HLA-B/C (HCA� and HC��; Dr. J. Nee�es, NKI, Amsterdam) and anti-
HLA-DR (LN�; Biotest AG, Dreieich, Germany) were considered negative when staining of 
tumor cells was absent in the presence of a positive internal control. EBER in situ hybridiza-
tion for EBV was performed according to manufacturer’s protocol (DAKO).
Immunoglobulin mutation analysis
DNA was isolated from paraﬃn tissue and IgH multiplex PCR and GeneScan analysis 
were performed as described.¹ Unlabeled PCR products were cloned and from both tumors 
�� colonies (�� for each duplicate PCR) were sequenced. Sequences were analyzed using 
IMGT/VQUEST¹³ and aligned using ClustalW¹⁴ and were deposited in GenBank (EF������ 
to EF������).
Results
In March ���� a male patient, age ��, was diagnosed with a stage IE, right temporal CNS 
DLBCL. Complete remission was achieved with chemotherapy (alternating high doses of 
MTX/Teniposide and high doses of MTX for � weeks, with � times intermi�ent intrathecal 
MTX), followed by radiotherapy (�� Gy in �� fractions). In June ����, the patient presented 
with a tumor of the le� testicle and a diagnostic orchidectomy revealed DLBCL. Restaging 
disclosed stage IE disease. The patient was treated with � times CHOP with intrathecal MTX 
and radiotherapy of the le� groin area and scrotum (�� Gy in �� fractions). In August ����, 
the patient developed neurological symptoms, most probably due to post-radiation encepha-
lopathy. Until September ���� no disease activity was found.
Both CNS and testicular DLBCL were CD�� positive and EBV negative. The CNS DLBCL 
was heterogeneous for CD��, negative for Bcl� and positive for MUM� (IRF�); the testicular 
DLBCL was negative for CD�� and positive for Bcl� and MUM�, compatible with an ABC-
like immunophenotype.¹ Both localizations showed loss of HLA-DR expression, the testicular 
DLBCL showed additional loss of HLA class I expression. Very few T cells (including CD�-
positive cytotoxic T cells) and macrophages were present in the micro-environment of the 
CNS lymphoma, while the numbers for both cell types were higher in the micro-environment 
of the testicular lymphoma. The T cells that were present were mostly CD� positive.
GeneScan analysis of IgH rearrangements showed identical rearrangements in both local-
izations, conﬁrming that the testicular DLBCL was a relapse from the CNS DLBCL. Sequence 
analysis revealed �� clones derived from the same rearrangement (C� – C�� and T� – T��). 
CDR� V-D-J junctional sequences showed highest homology to IGVH�-��*��, DH�-� and 
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JH�*��. A hypothetical consensus sequence, ‘shared CNS’, was considered as CNS DLBCL 
founder clone and carried �� mutations (��%) compared with the germline V�-��*�� allele, 
of which �� were located in a mutation hotspot or a directly adjacent codon (F����� �). Using 
the multinomial model��, signiﬁcant negative selection pressure on the framework regions 
was observed (p≤�.���). Considerable intraclonal heterogeneity was found at both lymphoma 
sites (F����� �).
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Figure 1. Alignment of hypothetical IgH consensus ‘shared CNS’ sequence with germline V3-
30*18, D2-2 and J5*02 allele sequences
Codon numbering according to IMGT13. Mutations in the ‘shared CNS’ consensus are indicated by asterisks under the germline 
sequence. Mutation hotspots (RGYW, WRCY and TAA motifs) are indicated in bold. Primer sequences are highlighted in grey.
                                                                      ______________CDR1-IMGT____
                       15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33
                       P   G   R   S   L   R   L   S   C   A   A   S   G   F   T   F   S   S   Y 
IGHV3-30*18           CCT GGG AGG TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGC TAT
                                                           *                    *      **   * *  
                                                           E                           N       H 
Shared CNS             CT GGG GGG TCC CTG AGA CTC TCC TGT GAA GCC TCT GGA TTC ACA TTC AAC AGT CAT
                      ___                                                                     ___
                       34  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56
                       G   M   H   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   V   I 
IGHV3-30*18           GGC ATG CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG GCA GTT ATA
                       *                    *  *    *               *     *             * ***   *
                       A                       R                           Q               S     
Shared CNS            GCC ATG CAC TGG GTC CGT CGG GCC CCA GGC AAG GGA CTG CAG TGG GTG GCG AGC ATT
                      ___________CDR2- IMGT______                                                
                       57  58  59  60  61  62  63  66  67  68  69  70  71  72  74  75  76  77  78
                       S   Y   D   G   S   N   K   Y   Y   A   D   S   V   K   G   R   F   T   I 
IGHV3-30*18           TCA TAT GAT GGA AGT AAT AAA TAC TAT GCA GAC TCC GTG AAG GGC CGA TTC ACC ATC
                        * **        *  **   * ***  **       *                                    
                           S           K       V   F                                             
Shared CNS            TCC AGT GAT GGC AAG AAA GTC TTT TAT GCC GAC TCC GTG AAG GGC CGA TTC ACC ATC
                                                                                                
                       79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97
                       S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   R   A   E 
IGHV3-30*18           TCC AGA GAC AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG AGA GCT GAG
                                      **  **  *    ** * *  *    *          *        *  *   ** ***
                                       N   G   D   R   V   F               S           T   V   S 
Shared CNS            TCC AGA GAC AAT AAC GGG GAC AGA GTA TTT CTA CAA ATG AGC AGC CTC ACA GTC AGC
                                                  ____________CDR3-IMGT__________________________
                       98  99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116
                       D   T   A   V   Y   Y   C   A   K           T   S   C               W   F 
IGHV3-30*18/N/D/N/J   GAC ACG GCT GTG TAT TAC TGT GCG AAA GA      ACC AGC TGC T           TGG TTC
                                  * *      *                                *             *      
                                   L       F               D   E           W   C   R   G   R     
Shared CNS            GAC ACG GCT CTC TAT TTC TGT GCG AAA GAT GAA ACC AGC TGG TGT CGG GGC CGG TTC
                      _______
                      117 118 119 120 121 122 123 124 125 126 127 128 129 130 131
                       D   P   W   G   Q   G   T   L   V   T   V   S   S         
IGHJ5*02              GAC CCC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G      
                       **                   *                                    
                       G                                                    G   K
Shared CNS            GGG CCC TGG GGC CAG GGC ACC CTG GTC ACC GTC TCC TCA GGT AAG
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Figure 2. Alignment of lymphoma IgH sequences with germline V3-30*18, D2-2 and J5*02 
allele sequences
C: sequences from CNS DLBCL, T: sequences from testicular DLBCL. Codon numbering according to IMGT.13 The sequence of the 
hypothetical consensus ‘shared CNS’ is included and mutations in this consensus are indicated by asterisks under the germline 
sequence. Additional mutations in lymphoma sequences are indicated relative to this consensus sequence. 
(continued on next page)
                                                                      ______________CDR1-IMGT____
                       15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33
                       P   G   R   S   L   R   L   S   C   A   A   S   G   F   T   F   S   S   Y 
IGHV3-30*18           CCT GGG AGG TCC CTG AGA CTC TCC TGT GCA GCC TCT GGA TTC ACC TTC AGT AGC TAT
                                                           *                    *      **   * *  
                                                           E                           N       H 
Shared CNS             CT GGG GGG TCC CTG AGA CTC TCC TGT GAA GCC TCT GGA TTC ACA TTC AAC AGT CAT
C5/C6/C7/C16           -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C18                    -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C2/C8/C10              -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C9/C11/C14/C17         -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C3                     -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C1/C13                 -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C4                     -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C12                    -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C15                    -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T2/T5/T7/T12/T13       -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T1/T3/T6/T9            -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T8                     -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T4                     -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T10                    -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T11                    -- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
                                                                                                 
                      ___                                                                     ___
                       34  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56
                       G   M   H   W   V   R   Q   A   P   G   K   G   L   E   W   V   A   V   I 
IGHV3-30*18           GGC ATG CAC TGG GTC CGC CAG GCT CCA GGC AAG GGG CTG GAG TGG GTG GCA GTT ATA
                       *                    *  *    *               *     *             * ***   *
                       A                       R                           Q               S     
Shared CNS            GCC ATG CAC TGG GTC CGT CGG GCC CCA GGC AAG GGA CTG CAG TGG GTG GCG AGC ATT
C5/C6/C7/C16          --- --- --- --- --- --- --- --- --- –A- --- --- --- --- --- --- --- --- ---
C18                   --- --- --- --- --- --- --- --- --- –A- --- --- --- --- --- --- --- --- ---
C2/C8/C10             --- --- --- --- --- --- --- --- --- –A- --- --- --- --- --- --- --- --- ---
C9/C11/C14/C17        --- --- --- --- --- --- --- --- --- –A- --- A-- --- --- --- --- --- --- ---
C3                    --- --- --- --- --- --- --- --- --- –A- --- A-- --A --- --- --- --- --- ---
C1/C13                --- --- --- --- --- --- --- --- --- –A- --- A-- --- --- --- --- --- --- ---
C4                    --- --- --- --- --- --- --- --- --- –A- --- A-- --- --- --- --- --- --- ---
C12                   --- --- --- --- --- --- --- --- --- –A- --- A-- --- --- --- --- --- --- ---
C15                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T2/T5/T7/T12/T13      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T1/T3/T6/T9           --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T8                    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T4                    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T10                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T11                   --- --- --- --- --- --- --- --- --G --- --- --- --- --- --- --- --- --- ---
                                                           D      R                              
                      ___________CDR2- IMGT______                                                
                       57  58  59  60  61  62  63  66  67  68  69  70  71  72  74  75  76  77  78
                       S   Y   D   G   S   N   K   Y   Y   A   D   S   V   K   G   R   F   T   I 
IGHV3-30*18           TCA TAT GAT GGA AGT AAT AAA TAC TAT GCA GAC TCC GTG AAG GGC CGA TTC ACC ATC
                        * **        *  **   * ***  **       *                                    
                           S           K       V   F                                             
Shared CNS            TCC AGT GAT GGC AAG AAA GTC TTT TAT GCC GAC TCC GTG AAG GGC CGA TTC ACC ATC
C5/C6/C7/C16          --- --- --- -A- --- -G- --- --- --- --- --- --- --- --- --- --- --- --- ---
C18                   --- --- --- -A- --- -G- --- --- --- --- --- --- --- --- --- --- --- --- ---
C2/C8/C10             --- --- --- -A- --- -G- --- --- --- --- --- --- --- --- --- --- --- --- ---
C9/C11/C14/C17        --- --- --- -A- --- -G- --- --- --- --- --- --- --- --- --- --- --- --- ---
C3                    --- --- --- -A- --- -G- --- --- --- --- --- --- --- --- --- --- --- --- ---
C1/C13                --- --- --- -A- --- -G- --- --- --- --- --- --- --- --- --- --- --- --- ---
C4                    --- --- --- -A- --- -GG --- --- --- --- --- --- --- --- --- --- --- --- ---
C12                   --- --- --- -A- --- -G- --- --- --- --- --- --- --- --- --- --- --- --- ---
C15                   --- --- --- --- --- -C- --- --- --- --- --- --- --- --- --- --- --- --- ---
T2/T5/T7/T12/T13      --- --- --- --- --- -C- --- --- --- --- --- --- --- --- --- --- --- --- ---
T1/T3/T6/T9           --- --- --- --- --- -C- --- --- --- --- --- --- --- --- --- --- --- --- ---
T8                    --- --- --- --- --- -C- --- --- --- --- --- --- --- --- --- --- --- --- ---
T4                    --- --- --- --- --- -C- --- --- --- --- --- --- --- --- --- --- --- --- ---
T10                   --- --- --- --- --- -C- --- --- --- --- --- --- --- --- --- --- --- --- ---
T11                   --- --- --- --- --- -C- --- --- --- --- --- --- --- --- --- --- --- --- ---
                                   D      R/T                                                    
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Figure 2 (continued)
If an additional mutation in a lymphoma clone leads to an amino acid replacement compared with the consensus sequence, 
the new amino acid is indicated below the sequence of T11. Mutation hotspots (RGYW, WRCY and TAA motifs) are indicated in 
bold. Primer sequences are highlighted in grey.
                                                                                                 
                       79  80  81  82  83  84  85  86  87  88  89  90  91  92  93  94  95  96  97
                       S   R   D   N   S   K   N   T   L   Y   L   Q   M   N   S   L   R   A   E 
IGHV3-30*18           TCC AGA GAC AAT TCC AAG AAC ACG CTG TAT CTG CAA ATG AAC AGC CTG AGA GCT GAG
                                      **  **  *    ** * *  *    *          *        *  *   ** ***
                                       N   G   D   R   V   F               S           T   V   S 
Shared CNS            TCC AGA GAC AAT AAC GGG GAC AGA GTA TTT CTA CAA ATG AGC AGC CTC ACA GTC AGC
C5/C6/C7/C16          --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C18                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C2/C8/C10             --- --- --- --- --- --- --- --- --- C-- --- --- --- --- --- --- --- --- ---
C9/C11/C14/C17        --- --- --- --- --- --- --- --- --- C-- --- --- --- --- --- --- --- --- ---
C3                    --- --- --- --- --- --- --- --- --- C-- --- --- --- --- --- --- --- --- ---
C1/C13                --- --- --- --- --T --- --- --- --- C-- --- --- --- --- --- --- --- --- ---
C4                    --- --- --- --- --- --- --- --- --- C-- --- --- --- --- --- --- --- --- ---
C12                   --- --- --- --- --- --- --- --- --- C-- --- --- --- --- --- --- --- --- ---
C15                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- -A- --- --- --- ---
T2/T5/T7/T12/T13      --- --- --- --- --- --- --- --- --- --- --- --- --- --- -A- --- --- --- ---
T1/T3/T6/T9           --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T8                    --- --- --- --- --- --- --- --- --- --- --- --- --- -A- --- --- --- --- ---
T4                    --- --- --- --- C-- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T10                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T11                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
                                      H                   L                N   N                 
                                                  ____________CDR3-IMGT__________________________
                       98  99 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116
                       D   T   A   V   Y   Y   C   A   K           T   S   C               W   F 
IGHV3-30*18/N/D/N/J   GAC ACG GCT GTG TAT TAC TGT GCG AAA GA      ACC AGC TGC T           TGG TTC
                                  * *      *                                *             *      
                                   L       F               D   E           W   C   R   G   R     
Shared CNS            GAC ACG GCT CTC TAT TTC TGT GCG AAA GAT GAA ACC AGC TGG TGT CGG GGC CGG TTC
C5/C6/C7/C16          --- --- --- --- --- --- --- --- -G- --- --- --- --- --- --- --- --- --- ---
C18                   --- G-- --- --- --- --- --- --- -G- --- --- --- --- --- --- --- --- --- ---
C2/C8/C10             --- --- --- --- --- --- --- --- -G- --- --- --- --- --- --- --- --- --- ---
C9/C11/C14/C17        --- --- --- --- --- --- --- --- -G- --- --- --- --- --- --- --- --- --- ---
C3                    --- --- --- --- --- --- --- --- -G- --- --- --- --- --- --- --- --- --- ---
C1/C13                --- --- --- --- --- --- --- --- -G- --- --- --- --- --- --- --- --- --- ---
C4                    --- --- --- --- --- --- --- --- -G- --- --- --- --- --- --- --- --- --- ---
C12                   --- --- --- --- --- --- --- --- -G- --- --- --- -A- --- --- --- --- --- ---
C15                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T2/T5/T7/T12/T13      --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T1/T3/T6/T9           --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T8                    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T4                    --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T10                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- -A- ---
T11                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
                          A                            R               N                   Q     
                      _______
                      117 118 119 120 121 122 123 124 125 126 127 128 129 130 131
                       D   P   W   G   Q   G   T   L   V   T   V   S   S         
IGHJ5*02              GAC CCC TGG GGC CAG GGA ACC CTG GTC ACC GTC TCC TCA G      
                       **                   *                                    
                       G                                                    G   K
Shared CNS            GGG CCC TGG GGC CAG GGC ACC CTG GTC ACC GTC TCC TCA GGT AAG
C5/C6/C7/C16          --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C18                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C2/C8/C10             --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C9/C11/C14/C17        --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C3                    --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C1/C13                --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C4                    --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C12                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
C15                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T2/T5/T7/T12/T13      --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T1/T3/T6/T9           --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T8                    --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T4                    --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T10                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
T11                   --- --- --- --- --- --- --- --- --- --- --- --- --- --- ---
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Discussion
We describe a unique patient with primary DLBCL of one immune sanctuary (CNS) and a 
very late, isolated relapse to another immune sanctuary (testis). Both localizations were clon-
ally related, and showed a high level of ongoing SHM and progressive loss of HLA expres-
sion. The observed SHM frequencies are considerably higher than in normal GC and post-GC 
B cells¹⁶ and nodal DLBCL.¹⁷ but comparable to the high SHM frequencies that are common 
in DLBCL of the testis and CNS.¹�⁷�⁸
We used IgH SHM analysis to deduce a model for the development of these lympho-
mas (F����� �). Since there was a common tumor subclone between both localizations (C�� 
and T�/T�/T�/T��/T�� were identical), we considered a subclone selection model as the most 
appropriate.¹⁸ According to this model, CNS DLBCL subclone C�� founded the testicular 
lymphoma. This model ﬁts with the clinical presentation (the testicular lymphoma developed 
a�er the CNS lymphoma).
None of our sequences contained nonsense or frameshi� mutations. Moreover, all 
sequences had a signiﬁcantly lower than expected R/S ratio in the framework region indicat-
ing maintenance of the overall structure of the functional B-cell receptor and the presence 
of selection pressure. This is reminiscent of the oligoclonal B cells from the CSF of patients 
with MS with a high load of ongoing SHM and strong preservation of the FR regions,¹⁹ and 
CSF derived B cells implicated in the generation of autoantibodies against GM� gangliosides 
in neuropathy.²⁰ A BLAST analysis of the CNS DLBCL CDR� sequence, as described before 
for MALT lymphomas,²¹ did not reveal any homology to antibodies directed against known 
autoantigens (data not shown).
Based on the results from the current study and previous reports we propose a hypothesis 
for the biological behavior of immune-privileged site-associated DLBCL. Both CNS and tes-
ticular DLBCL have IgH open reading frames with an extremely high load of ongoing somatic 
mutations, many leading to amino acid and idiotype changes.¹�⁷�⁸ In immune sanctuaries, a 
delicate balance exists between a tolerant/inhibitory immune response and an active cytotoxic 
immune response. Several mechanisms act together to provide an environment in which this 
balance is skewed towards tolerant or inhibiting responses.²²�²³ We hypothesize that the high 
load of mutations makes the tumor cells highly immunogenic and subject to an anti-idiotype 
immune response, and that in consequence the tumor cells initially can only survive within an 
immune sanctuary where this response is absent. When subsequently these lymphomas start 
to grow, the balance will eventually be disturbed, rendering the environment more permis-
sive for an anti-tumor cytotoxic immune response. This is substantiated by high numbers of 
inﬁltrating cytotoxic T cells in CNS and testicular DLBCL at the moment of clinical diagnosis.⁶ 
In the case presented here, this inﬁltrate is more pronounced in the testicular relapse than in 
the CNS localization. Under pressure of this immune reaction the ongoing remodeling of the 
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idiotype, in addition to progressive loss of HLA class II and HLA class I expression, might 
thus provide escape mechanisms for the tumor cells, necessary for their sustained survival 
and growth at these sites.
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2004
1996
Figure 3. Hypothetical model of the development of the CNS DLBCL and its subsequent 
relapse in the testis
 At a certain point in CNS DLBCL development (in or before 1996), ongoing hypermutation of a ‘shared CNS’ lymphoma clone 
resulted in 2 subclones (represented by open and ﬁlled cells respectively). While the major subclone (open cells) continued to 
diversify within the CNS environment, the minor subclone (ﬁlled cell) migrated through the bloodstream to the testis. Here it 
possibly stayed clinically dormant for many years to ﬁnally result, after 8 years, in a clinically manifest lymphoma (ﬁlled cells), 
which continued to accumulate mutations. In this ﬁgure mutations of individual clones relative to the consensus ‘shared CNS’ 
sequence are indicated by the mutated nucleotide number.
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Abstract
Primary diﬀuse large B-cell lymphomas of diﬀerent immune-privileged sites (IP-DLBCL) 
share many clinical and biological features, such as a relatively poor prognosis, preferential 
dissemination to other immune-privileged sites and deletion of the HLA region, which sug-
gests that IP-DLBCL represents a separate entity.
To further investigate the nature of IP-DLBCL, we investigated site-speciﬁc genomic aber-
rations in �� testicular, � central nervous system (CNS) and �� nodal DLBCL using array-CGH. 
We also determined minimal common regions of gain and loss. Using robust algorithms, the 
array-CGH data were combined with gene expression data to explore pathways deregulated 
by chromosomal aberrations.
Loss of �p��.�� – p��.�, including the HLA genes, was associated with both types of IP-
DLBCL, whereas gain of �p��.�-p��.� was associated with nodal DLBCL. Gain of ��q�� – q��.� 
and ��q��.�� – q��.�� was associated with CNS DLBCL and gain of ��q��.�� – q��.�� with 
testicular DLBCL. Analysis of candidate genes in site-speciﬁc regions and minimal common 
regions revealed two major groups of genes: one involved in the immune response, including 
regulation of HLA expression and another involved in apoptosis, including the p�� pathway. 
Many of these genes were also involved in homozygous deletions or high level gains.
The presence of both shared and site-speciﬁc aberrations in CNS and testicular DLBCL 
underlines the concept of IP-DLBCL but also indicates that IP-DLBCL of the CNS and testis do 
not form a single entity. The observed aberrations emphasize the importance of the deregula-




Primary diﬀuse large B-cell lymphoma (DLBCL) represents a heterogeneous group of 
lymphomas, which is reﬂected by clinical features, (histo)pathology, genomic aberrations and 
gene expression proﬁles (reviewed in ref. �). Two major subtypes of DLBCL are recognized, 
associated with diﬀerences in prognosis: the activated B cell-like (ABC) and germinal centre B 
cell-like (GCB).² These subtypes can be distinguished by gene expression proﬁle³�⁴ or immuno-
histochemistry⁵ and are associated with speciﬁc genomic aberrations.⁶ – ⁸
Primary testicular DLBCL and primary DLBCL of the central nervous system (CNS) are 
part of the immune-privileged site-associated DLBCL (IP-DLBCL) and share characteristics 
that separate them from nodal (non-IP) DLBCL. Besides having a diﬀerent clinical behavior⁹�¹⁰ 
and being predominantly of the ABC subtype,¹¹ – ¹³ we demonstrated a prominent loss of HLA 
class I and II (gene) expression, o�en caused by small interstitial deletions of chromosome 
�p��.�.¹⁴�¹⁵ This is associated with a downregulation of many immune-associated genes and a 
diminished inﬁltration of T cells.¹⁵ Deletions at �p��.� account for loss of HLA expression in 
approximately ��% of IP-DLBCL and in much less non-IP DLBCL cases,¹⁶ indicating the pres-
ence of alternative mechanisms.¹⁵
The shared characteristics between testicular and CNS DLBCL suggest that these IP-
DLBCL subtypes belong to the same homogeneous entity, that is separate from nodal non-IP 
DLBCL. So far no studies have compared genomic aberrations and gene expression between 
these groups of DLBCL. To that end, we explored genomic aberrations in testicular, CNS and 
nodal DLBCL. We combined these data with gene expression data obtained from the same 
cases and used robust algorithms to identify deregulated candidate genes in the aberrant 
chromosomal regions.
Materials and methods
Tissue sample collection and selection
Fi�y frozen samples from �� primary testicular, �� primary CNS and �� primary nodal 
DLBCL were collected from tissue banks at the University Medical Center Groningen, Leiden 
University Medical Center, Joseﬁne Ne�ens Institute, Ro�erdam; Netherlands Cancer Insti-
tute, Amsterdam, The Netherlands and University of Würzburg, Germany. Only samples 
from patients with Ann Arbor stage I or II were selected; the minimum number of tumor cells 
was ��%. All �� cases were used for gene expression analysis. Due to insuﬃcient quality of 
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array-comparative genomic hybridization (CGH) results we performed array-CGH analysis 
on �� of the �� cases: �� testicular, � CNS and �� nodal DLBCL. This study was approved by 
the institutional board of the UMCG and carried out in accordance with the modiﬁed Declara-
tion of Helsinki.
Gene expression microarray hybridization
Total RNA was isolated using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according 
to the manufacturers’ instructions. The samples were processed and hybridized on Aﬀymetrix 
HG U��� plus �.� oligonucleotide arrays (Aﬀymetrix, Santa Clara, CA, USA) following the 
protocol for eukaryotic samples in the Expression Analysis Technical Manual (h�p://www.
aﬀymetrix.com/support/technical/manual/expression_manual.aﬀx). The average probe array 
signals were scaled to a target signal of ��� using the GeneChip operating so�ware GCOS 
(Aﬀymetrix). Probesets with a signal below �� were discarded, leaving a ﬁnal dataset of ����� 
probesets.
ABC/GCB analysis
Array expression data of �� genes were used to determine the ABC/GCB subtype of the 
lymphomas with the linear predictor score (LPS) method.⁴ Nineteen testicular and � of the 
nodal DLBCL cases were previously characterized for ABC/GCB subtype on another micro-
array platform.¹¹ Of these, only � testicular DLBCL was reclassiﬁed from GCB to ABC.
Global gene expression analysis
Global gene expression comparison was performed using SAM analysis¹⁷ in the R package 
Siggenes (h�p://bioconductor.org/packages/�.�/bioc/html/siggenes.html). Before comparing 
global gene expression between testicular, CNS and nodal DLBCL, we excluded � datasets 
from the analysis: one ABC/GCB-speciﬁc set to avoid bias due to the skewed ABC/GCB pro-
portions in IP-DLBCL, and one set of genes that are diﬀerently expressed between normal 
CNS and normal testis to minimize the eﬀect of ‘contaminating’ normal tissue. The ABC/GCB-
speciﬁc dataset was determined by SAM analysis of the �� nodal DLBCL (� ABC and �� GCB) 
using a FDR cutoﬀ of �.��, and consisted of ��� genes (��� probesets). The genes that are 
diﬀerently expressed between normal testis and CNS tissue were identiﬁed using the GNF 
Human HG���A/GNF�H Tissue Atlas dataset.¹⁸ For each gene, the average expression values 
in normal testis and normal CNS tissue were determined. A�er testing several fold diﬀerence 
cutoﬀs (data not shown), ��� genes (��� probesets) that showed an �-fold or higher diﬀerence 
in expression between normal testis and normal CNS tissue were removed from the dataset 
for global gene expression analysis. The ﬁnal global gene expression comparison was per-




Genomic DNA was isolated using high salt a�er overnight SDS/proteinase K digestion and 
hybridized on an in house printed CGH array containing ~���� large genomic insert clones 
(provided by Dr. N. Carter, Welcome Trust Sanger Institute, UK), as previously described.¹⁹ 
Log� ratio values were analyzed using R packages DNACopy²⁰ and aCGH/MergeLevels²¹ 
to determine regions and levels of gain and loss. Hemi- and homozygous loss were deﬁned 
as one and two levels lower than normal respectively, gain as one or two levels higher than 
normal, and high level gain as three or more levels higher than normal.²¹ Chromosomes X 
and Y were excluded from further analysis, as well as heterochromatic regions, centromeres, 
ribosomal gene clusters and regions with known segmental duplications (grey areas in F��-
��� �). Minimal common regions (MCR) were deﬁned as the smallest regions of overlap that 
were smaller than �� Mb and present in at least � cases, of which at least � showed a limited 
aberration smaller than a whole chromosome or chromosomal arm. Overrepresentation of 
aberrations in diﬀerent localizations was assessed using the Fisher Exact test.
Combining expression and array-CGH data
ACE-it version �.�²² was used to ﬁnd genes for which expression levels correlate with 
genomic gain or loss. In short, for each lymphoma a status of gain, normal or loss was assigned 
(without distinction between hemi- and homozygous loss, or between single copy and high 
level gain) to each base pair position based on the array-CGH data. This status was mapped 
to the Aﬀymetrix probesets. The correlation of expression levels with genomic loss/gain was 
analyzed for each probe set by comparing expression in cases with loss/gain with expression 
in cases without aberrations using a one-sided non-parametric Wilcoxon test with Benjamini 
and Hochberg multiplicity correction. Genes for which expression correlated with gain or loss 
were annotated through the Entrez ID using DAVID (h�p://david.abcc.ncifcrf.gov/home.jsp), 
focusing on candidate genes with a known function in oncogenesis, normal B cells or B-cell 
neoplasms for which loss or gain would be functionally relevant for the tumor cells.
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Results
Diﬀerences in gene expression and genomic aberrations between testicular, CNS and nodal 
DLBCL
Using the LPS method, most testicular (�� of ��) and CNS (� of �) DLBCL were determined 
as ABC subtype, whereas in nodal DLBCL the balance was more equal: � of �� ABC and �� 
of �� GCB subtype. A�er removal of genes that were signiﬁcantly associated with the ABC/
GCB subtype or diﬀerently expressed between normal testis and CNS, global gene expres-
sion analysis of the � DLBCL groups revealed signiﬁcant diﬀerences: ���� genes were dif-
ferentially expressed between testicular and CNS DLBCL, ���� between testicular and nodal 
DLBCL, and ��� between CNS and nodal DLBCL. As expected,¹⁵ the expression of HLA class 
I and class II genes was signiﬁcantly lower in both testicular and CNS DLBCL, however Gene 
Set Enrichment Analysis²³ did not disclose any other biologically/functionally interesting pat-
terns (data not shown).
To investigate speciﬁc genomic aberrations in testicular and CNS DLBCL we performed 
array-CGH analysis (F����� �). The average number of aberrations per case was �.� in testicu-
lar, �.� in CNS and �.� in nodal DLBCL. Homozygous losses were found in �� regions, high 
level gains in � regions. The most common aberrations, present in at least ��% of CNS, testicu-
lar or nodal DLBCL cases, are shown in T���� �. T���� � summarizes the � regions showing 
signiﬁcant overrepresentation in one or more localizations.
To identify candidate genes in these � localization-speciﬁc regions we combined gene 
expression analysis with array-CGH analysis using ACE-it. Signiﬁcant genes whose expres-
sion levels correlated with genomic loss or gain were screened for a known function in 
oncogenesis, normal B cells or B-cell neoplasms (T���� �; full list of all signiﬁcant genes in 
S������������ T���� S�).  We described alterations of HLA and other genes at �p��.�� – p��.� 
previously;¹⁵ this region is not further discussed here. Gain of �p��.� – p��.� was associated 
exclusively with nodal DLBCL. This region contained �� signiﬁcantly altered genes includ-
ing candidates SUPT�L and anti-apoptotic BIRC� and BRE. Gain of both ��q�� – q��.� and 
��q��.�� – q��.�� was associated with CNS DLBCL. The ��q�� – q��.� region contained � sig-
niﬁcantly altered genes including candidates MDM� and YEATS� that are tightly associated 
with p��. The ��q��.�� – q��.�� region contained �� signiﬁcantly altered genes but none with 
a relevant function. Gain of ��q��.�� – q��.�� was associated with testicular DLBCL. This 
region is very gene dense and contained �� signiﬁcantly altered genes, including � candidates 
LILRA�, SPIB, BCL�L��, PAK� and PPP�C.
Analysis of gene expression in minimal common regions
We extended the combined array-CGH/expression analysis to the minimal common 
regions (MCR). In all �� DLBCL combined, �� regions met our criteria for an MCR: �� with 
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Figure 1. Genomic aberrations found in CNS, testicular and nodal DLBCL using array-CGH 
analysis
Losses (left) and gains (right) in testicular (orange), CNS (green) or nodal DLBCL (blue). Homozygous deletions and high level 
gains are indicated by thick colored bars. MCRs are indicated by thick black bars on the left- and rightmost side for each chro-












6p21.32 – p25.2 18 (45%) 5 (56%) 11 (69%) 2 (13%)
6q 20 (50%) 5 (56%) 10 (63%) 5 (33%)
15q12 – q21.1 12 (30%) 2 (22%) 5 (31%) 5 (33%)
17p12 – p13.3 13 (33%) 5 (56%) 4 (25%) 4 (27%)
Gain
1q21.3 – q32.1 15 (38%) 3 (33%) 7 (44%) 5 (33%)
7/7q 14 (35%) 2 (22%) 6 (38%) 6 (40%)
12 9 (23%) 4 (44%) 3 (19%) 2 (13%)
18p 11 (28%) 1 (11%) 4 (25%) 6 (40%)
18q 15 (38%) 2 (22%) 7 (44%) 6 (40%)

















6p21.32 – p25.2 1 – 34,919 18 (45%) 5 (56%) 11 (69%) 2 (13%) IP-DLBCL †
Gain
2p16.1 – p25.3 1 – 60,560 4 (10%) 0 (0%) 0 (0%) 4 (27%) nodal DLBCL SUPT7L, 
BIRC6, BRE
12q15 – q21.1 66,251 – 71,743 10 (25%) 5 (56%) 3 (19%) 2 (13%) CNS DLBCL MDM2, 
YEATS4
12q24.32 – q24.33 125,033 – 132,450 10 (25%) 5 (56%) 3 (19%) 2 (13%) CNS DLBCL —
19q13.12 – q13.43 37,665 – 63,812 13 (33%) 2 (22%) 11 (69%) 0 (0%) testicular DLBCL LILRA3, SPIB, 
BCL2L12, 
PAK4, PPP5C
Table 1. Most common genomic aberrations in CNS, testicular and nodal DLBCL
Aberrations in 30% or more of CNS, testicular or nodal DLBCL are listed. For each site the number of cases (and percentage) in 
which an aberration occurs is indicated.
Table 2. Site-speciﬁc aberrations and candidate genes
Aberrations that diﬀer in frequency between CNS, testicular and nodal DLBCL, and the candidate genes located therein. The 
number of cases (and percentage) in which an aberration occurs is indicated for each site. 
* p=< 0.05 using Fisher Exact test
† Gene expression in this region has been studied previously.15 
Mb: megabase.
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gain and �� with loss (black bars in F����� �). T���� � lists each region together with the num-
ber of genes signiﬁcant in ACE-it analysis and the candidate genes of interest (Full lists of 
signiﬁcantly altered genes in S������������ T���� S�; site-speciﬁc frequency data in S�����-
������� T���� S�).
Discussion
Primary IP-DLBCL share many features including a frequent dissemination to other 
immune-privileged sites.⁹�²⁴�²⁵ This suggests that these lymphomas share important biological 
features such as a similar expression of adhesion molecules, homing receptors or chemo-
kines and their receptors.²⁶�²⁷ We previously demonstrated that IP-DLBCL share a prominent 
downregulation of HLA class I and class II proteins, caused by small interstitial deletions at 
chromosome �p��.� in approximately ��% of cases.¹⁴�¹⁵ These observations led us to investi-
gate whether IP-DLBCL share more functional and genomic features that separate them from 
nodal non-IP DLBCL.
Our approach focused on genomic gains and losses deﬁned by array-CGH and the con-
comitant alterations in gene expression. This approach has the strong advantage that the gene 
expression alterations related to the microenvironment are ﬁltered out. Five chromosomal 
regions showed signiﬁcant diﬀerences in copy number between testicular, CNS and nodal 
DLBCL (T���� �). This included loss of �p��.�� – p��.�, which has been found previously in 
more than ��% of IP-DLBCL¹⁴�¹⁵ and in mediastinal large B-cell lymphomas (PMLBCL)²⁸ and 
causes loss of HLA class I and II expression.
Aberrations that were more frequently found in CNS DLBCL than in other cases were 
gain of ��q�� – q��.� and ��q��.�� – q��.��. We identiﬁed � candidate genes in the ﬁrst region: 
YEATS�, a repressor of the p�� pathway,²⁹ and MDM�, which is an inhibitor of p�� via ubiq-
uitin-dependent proteasomal degradation.³⁰ High expression of MDM� was recently reported 
to be associated with gain of chromosome �� and poor prognosis in mantle cell lymphoma³¹ 
and was also suggested to be a candidate in PMLBCL.²⁸ Weber et al.³² described a similar gain 
of ��q�� – �� and ��q�� in CNS DLBCL but they did not study other DLBCL, nor did they 
correlate their results with gene expression. They also identiﬁed a frequent high level gain 
of ��q��, however in our series gain of this region, with BCL� and MALT� being candidate 
genes, was not speciﬁc for CNS DLBCL (T���� � and S������������ T���� S�). According to 
the literature gain of ��q�� is o�en associated with ABC-type DLBCL rather than with a spe-
ciﬁc site of DLBCL.⁷�³⁰ High level gain of �p�� – p�� was also described in CNS DLBCL.³² We 
observed this gain in � CNS, � testicular and � nodal DLBCL (S������������ T���� S�); again 
indicating that many of the previously reported aberrations are not site-speciﬁc.















1p12 – p13.2 114,446 – 118,301 3.48 7 (18%) 31 17 4  (24%) —
1q32.2 – q32.3 203,602 – 208,089 4.49 5 (13%) 28 19 4  (21%) —
1q42.11 – q42.13 220,131 – 225,195 5.06 5 (13%) 51 39 11 (28%) PARP1
1q42.2 – q43 227,397 – 237,217 9.82 5 (13%) 45 33 9 (27%) EGLN1
2q14.3 – q22.2 127,254 – 143,617 16.36 4 (10%) 63 35 18 (51%) ERCC3, MAP3K2
5q13.1 – q13.2 67,677 – 71,660 3.98 5 (13%) 30 18 0 (0%) —
6p21.32 – p22.1 29,496 – 33,468 3.97 15 (38%) 154 111 * *
6q16.3 – q21 100,953 – 112,430 11.48 18 (45%) 52 36 24 (67%) REV3L, ATG5
6q23.3 – q24.2 137,302 – 144,432 7.13 18 (45%) 26 18 16 (89%) HIVEP2, PERP, PLAGL1, TNFAIP3
8q12.1 – q12.2 58,379 – 61,851 3.47 8 (20%) 9 6 5 (83%) —
8q13.1 – q13.3 67,344 – 72,600 5.26 6 (15%) 23 15 3 (20%) —
15q15.3 – q21.1 41,852 – 45,135 3.28 12 (30%) 27 19 10 (53%) PDIA3
17p13.2 3,399 – 6,065 2.67 12 (30%) 57 40 24 (60%) PFN1, ITGAE
17p12 – p13.1 7,438 – 12,92 5.48 8 (20%) 61 38 13 (34%) TP53, MAP2K4
19p13.2 – p13.3 5,893 – 12,007 6.11 5 (13%) 156 104 32 (31%) SMARCA4
Gain
1q23.2 – q23.3 156,697 – 160,910 4.21 12 (30%) 69 51 25 (49%) CD48, FREB, PEA15
1q31.1 – q31.2 185,925 – 198,884 12.96 12 (30%) 51 34 15 (44%) —
1q32.1 199,641 – 202,973 3.33 13 (33%) 50 32 9 (28%) —
1q44 241,691 – 245,523 3.83 8 (20%) 54 14 4 (29%) —
2p15 – p16.1 60,754 – 62,654 1.90 6 (15%) 12 12 4 (33%) —
3q13.12 – q13.13 107,671 – 111,576 3.90 8 (20%) 14 7 3 (43%) CD47
3q13.13 – q13.2 110,272 – 114,747 4.48 8 (20%) 27 21 5 (24%) —
3q26.33 – q28 183,353 – 189,732 6.38 9 (23%) 63 42 19 (45%) PARL
9p24.1 5,121 – 8,399 3.28 7 (18%) 20 16 4 (25%) PDCD1LG2
9q34.2 – q34.3 133,750 – 138,429 4.68 7 (18%) 86 61 1 (2%) —
11q22.3 – q23.1 108,393 – 112,571 4.18 6 (15%) 27 20 4 (20%) —
18q11.1 – q11.2 16,100 – 21,431 5.33 13 (33%) 22 20 3 (15%) —
18q21.1 – q21.33 45,188 – 59,059 13.87 15 (38%) 50 34 19 (56%) POLI, BCL2, MALT1
18q22.3 – q23 66,930 – 76,117 9.19 13 (33%) 25 23 12 (52%) —
19q13.41 – q13.43 56,504 – 63,812 7.31 13 (33%) 217 136 42 (31%) LILRA3
Table 3. MCR regions and candidate genes
Regions containing homozygous losses or high level gains are indicated in bold.  
* Gene expression in this region has been studied previously.15 
Mb: megabase.
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An aberration that was more frequently found in testicular DLBCL than in other cases 
was gain of ��q��.�� – q��.��. One array-CGH study⁷ reported on this gain in approximately 
��% of nodal ABC-type DLBCL, which could not be conﬁrmed in our nodal cases and was 
rarely identiﬁed in other series of B-cell lymphomas analyzed by array-CGH (ref. �� and Pro-
genetix database h�p://www.progenetix.de). Eighty-three genes in this region were higher 
expressed in cases with gain, of which � were interesting candidate genes. LILRA� is part of 
the leukocyte immunoglobulin-like receptor (LILR) gene family that contains both activating 
and inhibitory LIRL genes (reviewed in ref. ��). LILRA� exists in a soluble form. High expres-
sion by the lymphoma cells might therefore act as an antagonist (by competing for ligand) 
for activating LILRs on tumor-inﬁltrating lymphocytes. Three other candidate genes have 
a role in inhibition of apoptosis: BCL�L��, a recently discovered member of the BCL� gene 
family,³⁴ PAK�, which functions in TNFalpha-induced pro-survival pathways³⁵ and PPP�C, 
which inhibits p��-induced apoptosis as well as the MAP�K�/JNK pathway.³⁶ The ﬁ�h poten-
tial target gene is SPIB, which is deregulated by chromosomal translocation t(��;��) in the 
ABC-type DLBCL cell lineOCI-Ly�³⁷ and is a direct target of the transcription factor BOB� in 
normal B cells.³⁸ Interestingly, in two of our testicular DLBCL SPIB is located at the transition 
point of normal gain to high level gain, suggesting that deregulated expression is triggered 
by this rearrangement.
An aberration that was more frequently found in nodal DLBCL than in other cases was 
gain of �p��.� – p��.�. The candidates BIRC� and BRE are anti-apoptotic genes³⁹�⁴⁰ and SUPT�L 
(ARTC�) has been reported to be a ligand for anti-tumor regulatory T cells in melanoma,⁴¹ 
overexpression leading to suppression of the local anti-tumor immune response. Two well 
known targets of �p ampliﬁcation in DLBCL, REL and BCL��A,⁴² were not marked as poten-
tial targets in our series since REL expression did not correlate with gain, and BCL��A was 
located outside both the nodal-speciﬁc region and the MCR of �p�� – p��.�.
Apart from these site-speciﬁc chromosomal regions we identiﬁed MCRs and the candi-
date genes therein. Interestingly, a large proportion of the candidate genes from both analyses 
is involved in either apoptosis or regulation of the immune response/HLA (T���� �).
Regarding apoptosis, interesting candidates showing loss are PARP� (at �q��.��) that 
is fundamentally involved in DNA damage control and apoptosis in B-cell lymphomas,⁴³ 
the pro-apoptotic tumor suppressor gene MAP�K�⁴⁴ and TP�� (both located in the MCR at 
��p�� – p��.�). Loss of TP�� in DLBCL is associated with an aggressive clinical behavior.⁴⁵ Loss 
of �q��.� – q��.� (including homozygous deletion in � IP-DLBCL) was associated with down-
regulation of PERP, a direct eﬀector of apoptosis downstream of TP��. Using SNP analysis 
PERP was recently described as a candidate tumor suppressor gene for follicular lymphoma.⁴⁶ 
Interestingly, in our series �� of �� cases (� of � CNS, �� of �� testicular, �o f �� nodal) showed 
genomic aberrations aﬀecting the p�� pathway (loss of TP�� or PERP or gain of MDM�), sug-
gesting that this pathway is an important target for deregulation in DLBCL.
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Deletion of �p��.�� is the major mechanism by which HLA class II expression is lost in IP-
DLBCL.¹⁴�¹⁵ However, low expression without deletion is also found in IP-DLBCL and nodal 
DLBCL.¹⁵�¹⁶ Loss of SMARCA� and disruption of the interferon gamma pathway might be 
an alternative mechanism for loss of HLA expression. SMARCA� is located in the MCR at 
��p��.� and is essential for the interferon gamma-induced chromatin remodeling of class II 
transactivator (CIITA), which is the major regulator of HLA class II expression.⁴⁷ Another fac-
tor in the interferon gamma pathway, IFNGR�, is located in the MCR at �q��.� – q��, but its 
expression did not correlate with genomic loss in our data. We also observed loss (including 
homozygous deletion in two cases) of PDIA� at ��q��.�, which interacts with calnexin/calre-
ticulin and tapasin in the MHC class I peptide loading complex.⁴⁸
Apart from downregulation of HLA, other mechanisms are deployed to escape the anti-
tumor immune response. Gain (including high level gain) of �p��.� was associated with 
higher expression of PDCD�LG�, which is a ligand of the ‘programmed cell death receptor’ 
on T cells; binding to this receptor inhibits T-cell activation.⁴⁹ A consistently increased expres-
sion of this gene, o�en caused by gain of �p��, has been described in PMLBCL.⁵⁰ Also gain of 
LILRA� at ��q��, discussed earlier, belongs in this category.
In conclusion, genomic diﬀerences between IP-DLBCL and nodal DLBCL exist, the most 
prominent being the hemi- and homozygous deletions of �p��.�� in IP-DLBCL. The presence 
of diﬀerent aberrations in CNS and testicular DLBCL implies that these DLBCL do not form a 












































Table 4. Functionally interesting genes whose expression correlate with gain or loss
Genes involved in homozygous loss or high level gain are indicated in bold type. The genes are derived from Tables 2 and 3.
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we found a striking selection for genes involved in apoptosis, including the p�� pathway, as 
well as for genes that can modulate the anti-tumor immune response.
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�.�. A model of IP-DLBCL lymphomagenesis
The data presented in this thesis have been placed in a broader context of immune privi-
lege and immunoediting, resulting in a model that tries to explain why certain DLBCL arise 
speciﬁcally in immune-privileged sites and how these lymphomas interact with their envi-
ronment, eventually leading to a speciﬁc IP-DLBCL phenotype.
IP-DLBCL are highly immunogenic and survive only in immune-privileged sites
In ������� � an average frequency of somatic hypermutation of the immunoglobulin 
heavy chain (IgH) variable region of ��% in testicular DLBCL was reported and in ������� � 
a frequency of ��% in CNS DLBCL. These frequencies are comparable to those reported in 
other series of testicular¹ and CNS DLBCL² – ⁴ and are considerably higher than those in non-IP 
DLBCL which range from �% to ��%.⁵�⁶ The knowledge that the idiotype of B-cell lymphomas 
can be recognized as a tumor-associated antigen⁷�⁸ leads to the hypothesis that a high fre-
quency of IgH mutations makes a lymphoma highly immunogenic and that these lymphomas 
would beneﬁt from the absence of an anti-tumor immune response in an immune-privileged 
site.
Localization of a lymphoma in an immune-privileged site can be either an active or a 
passive process. In the active process the lymphoma cell selectively ‘homes’ to the immune-
privileged site by means of expression of speciﬁc adhesion molecules or chemokines. Expres-
sion of integrin LFA-� and its ligand ICAM-� has been reported in CNS lymphoma,⁹ as well 
as expression of CXCL�� (BCA-�) and its receptor CXCR�.¹⁰ – ¹² However these molecules are 
also expressed in lymph nodes,¹³ cutaneous lymphoma¹⁴ and gastric MALT lymphoma¹⁵ 
and therefore probably have a less speciﬁc role in a�racting B cells to extranodal sites in 
general, stimulating the formation of an ectopic lymphoid microenvironment¹⁶ and facili-
tating local dissemination. Testicular DLBCL lack expression of most adhesion molecules,¹⁷ 
and expression levels of CXCR� in testicular DLBCL were signiﬁcantly lower than in nodal 
DLBCL (unpublished result of the global gene expression analysis in C������ �). Based on 
these observations, there is no solid evidence supporting selective homing of lymphomas to 
the CNS or the testis. In the proposed model the localization of a lymphoma in an immune-
privileged site is a passive process, in which the highly immunogenic lymphoma cells with a 
high frequency of IgH mutations are only able to survive in the protective environment of an 
immune-privileged site while they are eliminated by the immune system everywhere else.
Progressive growth of IP-DLBCL disturbs immune privilege, leading to an inﬂux of immune cells
Historically immune privilege was thought to be equal to immune ignorance, caused by 
physical and physiological barriers that prevented exchange of antigens and immune cells 
between immune-privileged sites and the systemic immune system. It is now known that 
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immune privilege is actively maintained and that multiple mechanisms suppress the immune 
response and promote tolerance in immune-privileged sites.
Both CNS and testis possess a blood-organ barrier. The blood-brain barrier protects the 
brain from metabolites and toxins and prevents extensive inﬂux of immune cells into the brain. 
It is however not completely impermeable for such cells, as macrophages and CD�-positive 
T cells are found in the perivascular spaces under normal circumstances. Also peripherally 
activated T cells express integrins that enable them to migrate across the blood-brain barrier.¹⁸ 
The blood-testis barrier protects the sperm cells from the immune system, but the interstitial 
space, that also is considered immune privileged, is not protected by this barrier.¹⁹ So in both 
CNS and testis other mechanisms must be present that regulate the immune response. Both 
organs contain two populations of macrophages/dendritic cells. One is a residential macro-
phage population, which is rarely replenished, is incapable of stimulating T-cell proliferation 
and has reduced antigen presenting capacity. This population is thought to have an immu-
noregulating role, maintaining immune privilege. The other is an ‘inﬂammatory’ population 
of macrophages (and in CNS also dendritic cells) that is rapidly replenished from the circu-
lation and has full antigen presenting capabilities. In the CNS, microglia make up the resi-
dential population. The composition of the total population of macrophages/dendritic cells 
determines whether immune privilege can be maintained or is overcome by an inﬂammatory 
response. The mechanism regulating this composition is not completely clear, but probably 
involves local cells. In the CNS astrocytes and neurons regulate the microglial immune func-
tion, while in the testis cytokines produced by somatic cells such as Leydig cells, Sertoli cells 
and peritubular cells possibly play a role. Other mechanisms that can alter the threshold for 
an inﬂammatory response are neurodegeneration (pro-inﬂammatory) and androgen produc-
tion (anti-inﬂammatory).
Because immune privilege is such a delicately balanced system, it is very plausible that a 
growing lymphoma would disturb this balance, leading to a breach of immune privilege. One 
possible eﬀect is disruption of the blood-organ barrier, facilitating the inﬂux of T cells and 
APCs. Disruption of the blood-brain barrier could cause an uncontrolled entry of metabolites 
and toxins into the brain, leading to neuronal stress and activation of the innate immune 
response.¹⁸ The lymphoma could also cause tissue damage. In the CNS, damage to the neu-
rons will alter the regulation of the immune response. In the testis, tissue damage can result 
in the release of heat shock proteins that act as ‘danger signals’ and will enhance dendritic 
cell maturation.¹⁹ To induce its own growth and progression a lymphoma could also release 
pro-inﬂammatory cytokines such as IL-� or TNF.²⁰ The presence of a substantial number of 
activate T cells in IP-DLBCL provides evidence for a breach of immune privilege.²¹ The per-
centages of activated T cells as compared to the total number of T cells are also signiﬁcantly 
higher in IP-DLBCL (�� – ��%) than those in non-IP DLBCL (��%), reﬂecting the postulated 
higher immunogenicity of IP-DLBCL.
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IP-DLBCL undergo immunoediting and escape the immune response
A�er immune privilege is breached the IP-DLBCL will undergo immunoediting under 
pressure of the anti-tumor immune response, resulting in an immune escape phenotype. The 
frequent loss of HLA class I and II expression in IP-DLBCL may act as an immune escape 
mechanism in these lymphomas, which is supported by the ﬁnding that in some cases only 
part of the tumor cells show loss of expression and/or deletions of the HLA region.²² In ����-
��� � it is shown that loss of expression of HLA class II is associated with downregulation of 
numerous genes involved in inﬂammation and with a lower number of tumor-inﬁltrating T 
cells. It is important to note that HLA expression in this study was measured as expression 
of both lymphoma cells and cells from the lymphoma microenvironment together. When in 
another study T-cell numbers were compared between testicular DLBCL with and without 
HLA protein expression on the lymphoma cells only, there was no signiﬁcant diﬀerence.²¹ 
This could indicate that a loss of HLA class II expression on tumor cells alone is not suﬃcient 
to escape the immune response, because surrounding APCs that express MHC class II can still 
present the tumor-associated antigens through cross-presentation. The eﬀects of the down-
regulation of HLA class II were independent from the mechanism causing the downregula-
tion. This observation raises the questions why the IP-DLBCL so frequently have deletions 
of the HLA region and why the mechanisms of HLA class II downregulation diﬀer between 
IP-DLBCL and non-IP DLBCL.²³ One hypothesis is that these deletions, in particular the large 
hemizygous deletions, have an additional eﬀect on the expression of non-HLA genes located 
in the deleted region that would be beneﬁcial for the speciﬁc circumstances of IP-DLBCL. 
However it is shown in ������� � that this is not the case. Another explanation could be that 
in IP-DLBCL HLA alleles which are genetically more fragile and therefore more susceptible 
to deletions are overrepresented, although a study on HLA-DR and HLA-DQ alleles in �� 
IP-DLBCL, �� nodal DLBCL and ���� normal cases failed to ﬁnd evidence for the signiﬁcant 
association of overrepresented alleles with deletions in testicular DLBCL.²⁴ A third possible 
explanation, ﬁ�ing the proposed model, might be that the high immunogenicity of IP-DLBCL 
requires a more permanent means of HLA downregulation, as opposed to the less immuno-
genic non-IP DLBCL that o�en use some form of (reversible) transcriptional control like the 
downregulation of CIITA.²³
The case report presented in ������� � sheds some more light on the process of immuno-
editing in IP-DLBCL. The primary CNS DLBCL showed a low number of inﬁltrating T cells 
and macrophages, indicating a low immune pressure. This lymphoma had only lost HLA 
class II expression. There was a much larger number of inﬁltrating T cells and macrophages 
present in the testicular biopsy, reﬂecting a stronger anti-tumor immune response. When the 
CNS lymphoma clone (which was only adapted to a low immune pressure) arrived in the tes-
tis the equilibrium phase started, in which the stronger immune system was able to suppress 
lymphoma growth for a long period of time. Only a�er � years the immunoediting process 
resulted in a lymphoma that had adapted to the stronger immune pressure by downregula-
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tion of both HLA class I and II and thus could escape the immune response to become clini-
cally manifest.
Also in a larger series of IP-DLBCL the CNS DLBCL showed a lower number of inﬁltrat-
ing T cells and lower frequency of LOH in the HLA region than testicular DLBCL.²¹�²⁵ If the 
immune pressure in CNS DLBCL is indeed generally lower than in testicular DLBCL this 
could explain why relapse from the testis to the CNS is more frequent than vice versa.
�.� IP-DLBCL can be considered as a separate subentity of DLBCL
The ﬁrst step towards a subclassiﬁcation of DLBCL into IP- and non-IP DLBCL was made 
by proposing an IP-DLBCL-speciﬁc model of lymphomagenesis. Further arguments for this 
subclassiﬁcation are found in �������� � ��� � of this thesis. Here it is shown that there is a 
notable diﬀerence in the ABC/GCB immunophenotype of IP- and non-IP DLBCL. While in 
non-IP DLBCL the distribution between the ABC and GCB subtypes is reasonably balanced, 
in IP-DLBCL the ABC subtype is much more frequent (��% in testicular and ��% in CNS 
DLBCL). Subtyping of IP-DLBCL using gene expression proﬁling was unambiguous but a 
signiﬁcant proportion of ABC-type testicular DLBCL showed an ambiguous protein expres-
sion pa�ern of both CD�� and MUM�, which is rare in non-IP DLBCL.²⁶�²⁷ This illustrates 
the importance of distinguishing IP-DLBCL from non-IP DLBCL: since the most widely used 
immunohistochemistry classiﬁer²⁶ is based on a population of non-IP DLBCL, it does not 
accommodate for this expression pa�ern and would have misclassiﬁed these cases as GCB-
type DLBCL.
The association of certain genomic aberrations with either IP- or non-IP DLBCL (������� 
�) also supports the proposed subclassiﬁcation. The presence of aberrations that were asso-
ciated with only CNS DLBCL or only testicular DLBCL indicates there would still be some 
heterogeneity in the proposed IP-DLBCL subtype and might reﬂect the diﬀerences in immune 
pressure as discussed in the previous paragraph.
In conclusion, this thesis shows that IP-DLBCL have speciﬁc molecular characteristics that 
probably underlie their speciﬁc localization and clinical behavior. The interaction between 
the lymphoma and its microenvironment further shapes the IP-DLBCL geno- and phenotype. 
These ﬁndings underwrite the subclassiﬁcation of DLBCL into IP- and non-IP DLBCL.
General Discussion
100
�.� Recommendations for further research
Target gene analysis of the genomic aberrations in ������� � showed that DLBCL use all 
three means of immune escape: avoiding recognition, suppressing the immune response and 
resisting apoptosis induced by immune cells. Some aberrations were site-speciﬁc, supporting 
the view that the mechanisms used to accomplish immune escape diﬀer between IP- and non-
IP DLBCL. Immunohistochemical analysis of the described candidate genes and their down-
stream targets is needed to aﬃrm their proposed role in immune escape and ﬂuorescence 
in situ hybridization (FISH) analysis could conﬁrm the genomic aberrations. Because both 
techniques are suitable for the analysis of paraﬃn-embedded tissue, the number of cases can 
be increased. This would allow analysis of target genes for IP- and non-IP DLBCL separately, 
to investigate whether immune escape mechanisms indeed diﬀer between IP- and non-IP 
DLBCL.
Since genomic aberrations are only present in the lymphoma cells and not in the cells of 
the microenvironment, analysis of gene expression changes associated with these aberrations 
focuses on the intrinsic properties of the lymphoma cells. In the IP-DLBCL lymphomagen-
esis model however it is believed that the interactions between the lymphoma and the micro-
environment determine the outcome of the immunoediting process and the immune escape 
mechanism that is chosen. Global gene expression proﬁling on whole tissue sections includes 
information on the microenvironment. This analysis was performed in ������� � using gene 
set enrichment analysis (GSEA) but biologically meaningful diﬀerences between CNS, testi-
cular and nodal DLBCL could not be extracted from the large lists of signiﬁcant genes. If these 
data are to be used for further analysis a functional reduction of the number of signiﬁcant 
genes would probably be beneﬁcial, such as the exclusion of genes that are not related to 
immunity or the exclusion of genes that are associated with genomic aberrations and thus 
with lymphoma-intrinsic eﬀects and not with the eﬀect of the microenvironment.
Another, probably more promising approach to investigate the interaction between the 
lymphoma and its microenvironment would be immunohistochemistry using speciﬁc mark-
ers for lymphocyte and macrophage subsets and antibodies against immune (escape)-related 
proteins such as cytokines, costimulatory proteins and proteins involved in apoptosis.
A new area of research that has developed over the past few years investigates the role of 
microRNAs in B-cell development and lymphomagenesis (reviewed in ref. ��). MicroRNAs 
are non-coding RNA’s of ~�� nucleotides that function primarily as translational repressors 
by binding to complimentary target sequences in the �’ untranslated region of mRNA mol-
ecules. A current study on a small set of �� microRNAs with known involvement in B-cell 
development or lymphomagenesis in a series of IP- and non-IP DLBCL showed a higher 
expression of MIRN���, potentially targeting Bcl�,²⁹ in testicular DLBCL and a higher expres-




As discussed, diﬀerent techniques are used to investigate diﬀerent aspects of the interac-
tion between IP-DLBCL and the microenvironment. Combining the results from these tech-
niques will give more insight into the biology of IP-DLBCL. To get an even more complete 
overview of IP-DLBCL as a separate subgroup of DLBCL, comparisons could be made not 
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Diﬀuse large B-cell lymphoma (DLBCL) is currently regarded as one disease entity in 
the WHO classiﬁcation, but is very heterogeneous in regard to clinical features such as site 
of presentation, dissemination pa�ern and prognosis. Based on site of presentation, DLBCL 
can be subdivided into nodal and extranodal DLBCL. Extranodal DLBCL comprise ��% of 
all DLBCL cases and present mostly in the gastrointestinal tract, but also in skin, bone and 
lung, central nervous system (CNS) and testis. The CNS and testicular DLBCL both arise in 
immune-privileged sites and are therefore referred to as immune-privileged site-associated 
DLBCL (IP-DLBCL). While both nodal and extranodal DLBCL subgroups are no less het-
erogeneous than DLBCL in general, the IP-DLBCL are much more homogeneous and share 
several clinical and molecular characteristics such as a poor prognosis, frequent dissemina-
tion to other immune-privileged sites and high expression levels of Bcl� in the absence of 
t(��;��) translocations. A very characteristic feature for IP-DLBCL, which is much rarer in 
nodal DLBCL or non-IP extranodal DLBCL, is the loss of expression of HLA class I and II 
proteins, o�en associated with hemi- and homozygous deletion of the HLA genes and sur-
rounding HLA region on chromosome �p��.�.
In the project presented in this thesis we studied the eﬀects of the loss of HLA expression 
and �p��.� deletions in IP-DLBCL. We also investigated whether IP-DLBCL share additional 
molecular characteristics that separate them from non-IP DLBCL, which might indicate they 
should be regarded as a separate entity.
Previous studies in IP-DLBCL revealed two types of deletions in the HLA region on chro-
mosome �p��.�. Small homozygous deletions only aﬀected the HLA-DR and -DQ genes, 
whereas hemizygous deletions were larger and aﬀected the whole HLA region. In ������� 
� we performed cDNA microarray expression analysis on a series of testicular and nodal 
DLBCL to investigate the impact of the homo- and hemizygous deletions on HLA gene 
expression as well as the global gene expression pa�erns of testicular DLBCL. This analysis 
revealed that HLA-DR and -DQ gene expression was severely downregulated in most testicu-
lar DLBCL regardless of the presence of deletions, suggesting that loss of HLA class II expres-
sion is a very important feature in testicular DLBCL that is regulated by multiple mechanisms. 
Indeed, in the cases without deletions the expression levels of HLA-DR and -DQ correlated 
with the expression levels of the MHC class II transactivator (CIITA) gene. Although neither 
hemizygous nor homozygous deletions had any major eﬀect on global gene expression pat-
terns, downregulation of HLA-DR gene expression was signiﬁcantly associated with a strong 
downregulation of many immune-associated genes and a lower number of inﬁltrating reac-
tive T cells, indicating a diminished anti-tumor immune response. These results support the 
idea that loss of HLA-DR expression functions as an immune escape mechanism in testicular 
DLBCL.
Recent eﬀorts to ﬁnd a molecular basis of the clinical heterogeneity in DLBCL have led 
to the division into a subtype with a germinal center B-cell phenotype (GCB) and a subtype 
with an activated B-cell phenotype (ABC). These subtypes diﬀer in their immunophenotype, 
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gene expression proﬁle and the presence of ongoing immunoglobulin heavy chain (IgH) 
somatic hypermutation (SHM). They are also associated with speciﬁc genomic aberrations. 
Most important, DLBCL of the ABC subtype have a worse prognosis than those of the GCB 
subtype. In ������� � we determined the subtype of testicular DLBCL using immunophe-
notyping, gene expression analysis, and IgH SHM analysis. There were no testicular DLBCL 
with a GCB immunophenotype since all cases showed expression of the ABC marker MUM� 
(IRF�). Thirty-six percent of these showed additional expression of GCB marker CD�� and 
were classiﬁed as an ‘ambiguous immunophenotype’ since they expressed both GCB and ABC 
markers. The remaining ��% were negative for CD�� protein expression and thus were clas-
siﬁed as the ABC immunophenotype. Subsequent gene expression analysis showed that both 
ambiguous and ABC immunophenotypes shared the same ABC-like gene expression pa�ern. 
The frequency of somatic hypermutation of IgH genes was very high in testicular DLBCL, 
higher than had been reported for nodal DLBCL and comparable to frequencies found in CNS 
DLBCL. Low level intraclonal variation indicating ongoing mutation could only be conﬁrmed 
in one case. We conclude that testicular DLBCL have uniform ABC subtype characteristics, 
despite some cases expressing CD��. These ﬁndings also indicate that currently used immu-
nophenotyping algorithms to determine the subtype of nodal DLBCL, which classify all CD�� 
positive cases as GCB subtype regardless of the expression of other markers, might not be 
fully applicable to IP-DLBCL where cases express both CD�� and MUM� more o�en than in 
nodal DLBCL.
IP-DLBCL have a very characteristic dissemination and relapse pa�ern, o�en restricted to 
other immune-privileged sites. Relapses of primary CNS DLBCL are conﬁned to the CNS in 
��-��% of cases. In ������� � we describe a unique patient who was diagnosed with primary 
CNS DLBCL and had a relapse conﬁned to the testis � years a�er initial diagnosis. This case 
provided us with the opportunity to investigate the process of immunoediting in IP-DLBCL 
over time. Both CNS and testicular DLBCL were classiﬁed as the ABC subtype by immuno-
phenotyping. There was progressive loss of HLA protein expression: the CNS DLBCL had 
lost HLA class II expression and the relapse in the testis showed additional loss of HLA class 
I expression. While very few T cells and macrophages were present in the environment of the 
CNS DLBCL, the numbers were higher in the testicular DLBCL. Analysis of the mutations 
in the IgH genes showed a high mutation frequency comparable to those presented in ����-
��� �. The intraclonal heterogeneity was consistent with the clinical presentation and indi-
cated that the testicular DLBCL developed from a subclone of the CNS DLBCL, a�er which 
both lymphomas independently accumulated further mutations. Based on this case and the 
results from the previous chapters we proposed a simple model for lymphomagenesis. In this 
model the high load of somatic hypermutations make the lymphoma cells very immunogenic 
and susceptible to an anti-idiotype response, so that they can only survive an immune a�ack 
within an immune-privileged site. The presence of the growing lymphoma will then interfere 
with the actively maintained immune privilege leading to a shi� towards an active immune 
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response. Under pressure of this immune response the process of immunoediting will start, 
leading to escape mechanisms such as the ongoing remodeling of the idiotype and progres-
sive loss of HLA expression.
Together with the literature the results presented in the previous chapters suggest that IP-
DLBCL form a relatively homogeneous subgroup within the DLBCL in general. To investigate 
whether they also share characteristic genomic aberrations we analyzed a series of testicular, 
CNS and nodal DLBCL using array-comparative genomic hybridization (CGH) (������� �). 
In addition to �� common regions of loss or gain, we found that some aberrations were asso-
ciated with site of presentation. Gain of �p��.� – p��.� was associated with nodal DLBCL. 
Loss of �p��.�� – p��.�, including the HLA region, was associated with IP-DLBCL (both 
CNS and testicular), conﬁrming previous results. We also found gain of ��q�� – q��.� and 
��q��.�� – q��.�� associated with CNS DLBCL and gain of ��q��.�� – q��.�� associated with 
testicular DLBCL. The presence of genomic diﬀerences between nodal DLBCL and IP-DLBCL 
supports the idea of IP-DLBCL as a speciﬁc or separate subgroup of DLBCL, but the presence 
of site-speciﬁc aberrations in CNS and testicular DLBCL also implies that these IP-DLBCL do 
not form a single entity. By combining the array-CGH data with gene expression microarray 
data we explored which genes and biological pathways were deregulated by the genomic 
aberrations. The majority of candidate target genes was involved either in apoptosis or in the 
modulation of the anti-tumor immune response, emphasizing the importance of deregulation 
of these pathways in lymphomagenesis.
In the ﬁnal chapter (������� �) the results presented in this thesis are placed in a broader 
context of immune privilege and immunoediting, leading to an in-depth discussion of the 
model for IP-DLBCL-speciﬁc lymphomagenesis that was proposed in a simple form in ����-
��� �. The discussion concludes with further arguments for a subclassiﬁcation of DLBCL into 







Het immuunsysteem is het natuurlĳke verdedigingsmechanisme van het menselĳk 
lichaam en draagt onder andere zorg voor de afweer tegen infecties door lichaamsvreemde 
organismen zoals virussen en bacteriën. Wanneer het immuunsysteem in actie komt tegen 
een infectie wordt een ontstekingsreactie in gang gezet. Hoewel dit proces essentieel is voor 
de bescherming van het lichaam, kan deze ontstekingsreactie zelf ook schadelĳk zĳn en het 
omringende normale weefsel beschadigen. Om te voorkomen dat door een ontstekingsreactie 
de normale functie van vitale structuren zoals de hersenen, het oog en de testis (teelballen) 
in gevaar komt, is in deze structuren de immuunreactie onderdrukt. Dit zĳn zogenaamde 
‘immune-privileged sites’. Hetzelfde mechanisme zorgt ervoor dat tĳdens de zwangerschap 
de foetus, die beschouwd kan worden als een lichaamsvreemd organisme, niet wordt aange-
vallen door het immuunsysteem.
Naast de afweer tegen infecties speelt het immuunsysteem ook een grote rol bĳ kanker. 
Kanker ontstaat wanneer een normale, lichaamseigen cel ontregeld raakt en ongecontroleerd 
begint te groeien en te delen, waardoor een tumor wordt gevormd. Tĳdens dit proces veran-
dert het erfelĳk materiaal in de tumorcellen en produceren de tumorcellen eiwi�en die de 
oorspronkelĳke normale cel niet produceerde. Uiteindelĳk zĳn de tumorcellen zo sterk ver-
anderd ten opzichte van de normale cel dat ze door het immuunsysteem als lichaamsvreemd 
worden gezien en een anti-tumor immuunreactie in gang wordt gezet.
Tumorcellen kunnen zodanig ontregeld zĳn dat ze continu blĳven veranderen, ona�an-
kelĳk van elkaar, zodat er binnen een tumor kleine verschillen ontstaan tussen de tumor-
cellen. De meeste van deze veranderingen zullen geen gevolgen hebben voor de anti-tumor 
immuunreactie en daarom zal het merendeel van de tumorcellen worden vernietigd door het 
immuunsysteem. Echter sommige veranderingen zullen ervoor zorgen dat de tumorcellen 
niet meer herkend of vernietigd kunnen worden door het immuunsysteem, of dat de tumor-
cellen op hun beurt stoﬀen produceren die de immuuncellen kunnen vernietigen. Deze ver-
anderingen noemen we ‘immune escape’ mechanismen. Het kleine aantal tumorcellen dat 
deze veranderingen hebben ondergaan kan verder blĳven groeien en delen, wat resulteert in 
een tumor die resistent is geworden tegen het immuunsysteem. Dit proces waarbĳ een tumor 
door interactie met het immuunsysteem ‘evolueert’ wordt ‘immunoediting’ genoemd.
De tumoren die in dit proefschri� zĳn onderzocht zĳn ‘diﬀuus grootcellige B-cel lymfomen’ 
(DLBCL). Lymfomen zĳn tumoren die zĳn ontstaan uit ontregelde immuuncellen. Onder de 
noemer DLBCL valt een heterogene (gevarieerde) groep lymfomen, met onderling veel ver-
schil in klinische aspecten zoals lokalisatie, patroon van uitzaaiing en prognose. De meeste 
bevinden zich in de lymfeklieren, dit zĳn de nodale lymfomen. Anderen bevinden zich buiten 
de lymfeklieren, dit zĳn de extranodale lymfomen. Deze komen voor op plaatsen als de huid, 
bo�en, longen, maag, hersenen en testis. De hersenen en testis zĳn immune-privileged sites, 
en daarom worden DLBCL die hier voorkomen ook ‘immune-privileged site-geassocieerde’ 
lymfomen (IP-DLBCL) genoemd. Deze IP-DLBCL van de hersenen en testis hebben een aantal 
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eigenschappen gemeen en onderscheiden zich hiermee van de overige DLBCL. Ze hebben een 
relatief slechte prognose terwĳl uitzaaiingen zich vaak beperken tot de immune-privileged 
sites. Zo zaait een primair lymfoom van de testis vaak uit naar de hersenen. Een andere, 
zeer karakteristieke eigenschap van IP-DLBCL is het verlies van de productie van de human 
leukocyte antigen (HLA) eiwi�en, wat is geassocieerd met deleties (het verlies van chromo-
somaal materiaal) van chromosoom �p��.�. Dit is veel zeldzamer in de overige DLBCL. Het 
HLA systeem fungeert als de ‘keuringsdienst van waren’ van het lichaam, waarbĳ de HLA 
eiwi�en de ‘obers’ zĳn (zie ‘De HLA ober’), die de veranderde, lichaamsvreemde eiwi�en uit 
de lymfoomcel presenteren aan het immuunsysteem zodat het immuunsysteem weet dat de 
cel moet worden vernietigd. Wanneer deze HLA eiwi�en niet meer door het lymfoom worden 
geproduceerd kunnen de vreemde eiwi�en ook niet meer aan het immuunsysteem worden 
gepresenteerd waardoor het lymfoom onopgemerkt blĳ�. Dit zou dus een immune escape 
mechanisme kunnen zĳn voor IP-DLBCL. Chromosoom �p��.� is het gebied op chromosoom 
� waar de HLA genen liggen. Aangezien deze genen de ‘blauwdrukken’ voor de productie 
van de HLA eiwi�en vormen is de deletie van deze genen dus een mogelĳke oorzaak voor het 
verlies van de eiwitproductie.
Met het huidige onderzoek is geprobeerd meer opheldering te krĳgen over de moleculaire 
achtergrond voor het speciﬁeke biologische gedrag van IP-DLBCL. Ten eerste werd onder-
zocht welke rol het immuunsysteem speelt en wat het eﬀect van HLA verlies hierop is. Dit is 
ook van belang voor de ontwikkeling van nieuwe therapieën. Een vaak gebruikte therapeu-
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Het HLA systeem is de ‘keuringsdienst van waren’ voor het menselijk 
lichaam. De HLA eiwitten fungeren hierbij als ‘obers’. Eiwitten (vissen) die 
zich in de cel (de keuken) bevinden worden door speciﬁeke mechanismen 
(de koks) verwerkt tot kleinere fragmenten (vissticks). Vervolgens worden 
deze fragmenten gekoppeld aan een speciale groeve (het dienblad) in de 
HLA eiwitten (de obers). Deze HLA eiwitten gaan naar het oppervlak van 
de cel (de keuken uit) en presenteren de fragmenten aan de immuuncel-
len (de keuringsdienst) die zich in de omgeving (het restaurant) van de 
cel bevinden. Wanneer de fragmenten worden herkend als lichaamseigen 
(lekkere vissticks) zullen de immuuncellen geen actie ondernemen (een 
goede review). Wanneer er een bacterie of virus aanwezig is in de cel of 
wanneer een lymfoomcel een veranderd eiwit produceert (een rotte vis) 
wordt deze op dezelfde manier tot fragmenten verwerkt. De immuuncellen 
herkennen deze fragmenten als lichaamsvreemd (bedorven vissticks) en 
zullen vervolgens de geïnfecteerde cel of tumorcel vernietigen (de keuken 





tische strategie is om de anti-tumor immuunreactie op te wekken met medicĳnen. Dit kan 
via verschillende routes en het is daarom van groot belang om te weten via welke routes het 
lymfoom de immuunreactie ontwĳkt of remt, zodat de juiste route voor therapie gekozen kan 
worden. Ook werd gezocht naar verdere eigenschappen waarop IP-DLBCL zich onderscheidt 
van overige DLBCL. IP-DLBCL vallen in de huidige lymfoomclassiﬁcatie nog onder de grote 
groep DLBCL en worden ook in grote lĳnen op dezelfde manier behandeld. Als er genoeg 
aanwĳzingen zĳn dat IP-DLBCL een aparte groep vormt zou ervoor gekozen kunnen worden 
om IP-DLBCL als aparte ziekte in de classiﬁcatie van lymfomen op te nemen. Dit zou vervol-
gens de weg kunnen vrĳmaken voor een aangepaste behandelmethode die beter past bĳ het 
biologische karakter van IP-DLBCL en daardoor ook beter zou kunnen werken.
In het onderzoek dat is beschreven in ��������� � werd de rol van de immuunreactie bĳ 
het gedrag van IP-DLBCL bestudeerd. Er is aangetoond dat de interactie tussen het lymfoom 
en het immuunsysteem inderdaad erg belangrĳk is in DLBCL. Verlies van HLA productie 
in IP-DLBCL was geassocieerd met verlaagde productie van talloze andere moleculen met 
een functie in de immuunreactie. Bovendien was het aantal aanwezige immuuncellen lager 
bĳ de lymfomen met verlies van HLA productie. Samen duidt dit erop dat verlies van HLA 
productie een belangrĳk immune escape mechanisme is in IP-DLBCL. Ook de veel voorko-
mende chromosomale afwĳkingen (verlies van chromosomaal materiaal of de aanwezigheid 
van extra chromosomaal materiaal) hadden eﬀect op moleculen die betrokken zĳn bĳ de 
immuunreactie en bĳ de celdood (��������� �). Dit is opnieuw een aanwĳzing dat regulatie 
van de anti-tumor immuunreactie erg belangrĳk is in DLBCL.
H�������� � rapporteert over een patiënt met een IP-DLBCL van de hersenen dat � jaar 
later uitsluitend is uitgezaaid naar de testis. Door de mutaties (veranderingen) in het IgH gen 
in de individuele lymfoomcellen te volgen werd duidelĳk dat één van de lymfoomcellen van 
het DLBCL van de hersenen zich had losgemaakt en naar de testis was gemigreerd, waar deze 
was uitgegroeid tot het DLBCL van de testis. Bovendien liet het lymfoom progressief verlies 
van HLA productie zien.
Naast de studie naar de rol van de immuunreactie werd ook onderzocht of er additionele 
karakteristieke eigenschappen bestaan die IP-DLBCL kunnen onderscheiden van de overige 
DLBCL. In een poging de heterogeniteit van DLBCL te verkleinen, zĳn in de recente litera-
tuur een aantal manieren onderzocht om DLBCL in subgroepen in te delen. In één van de 
belangrĳkste onderzoeken worden DLBCL in twee subgroepen ingedeeld: ABC DLBCL en 
GCB DLBCL. Deze subgroepen zĳn gebaseerd op de overeenkomst tussen de lymfoomcellen 
en verschillende soorten normale B cellen (geactiveerde B cellen, Activated B Cells en follikel 
centrum B cellen, Germinal Center B cells). Ze verschillen in moleculaire karakteristieken en 
de productie van speciﬁeke eiwi�en. Ze hebben ook elk hun eigen karakteristieke chromo-
somale afwĳkingen. Uit veel studies komt bovendien naar voren dat de prognose van ABC 
DLBCL slechter is dan die van GCB DLBCL. In ��������� � werd aangetoond dat IP-DLBCL 
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van de testis bĳna allemaal tot de ABC DLBCL behoren. Hiermee onderscheiden ze zich van 
de overige DLBCL, die ongeveer gelĳk zĳn verdeeld over de twee subgroepen. In hetzelfde 
hoofdstuk is beschreven dat het aantal mutaties in het IgH gen van IP-DLBCL veel hoger is 
dan het aantal dat bekend is in overige DLBCL.
In ��������� � werd onderzocht of er voor IP-DLBCL ook karakteristieke chromosomale 
afwĳkingen bestaan, zoals zĳn beschreven voor ABC- en GCB DLBCL. Er werden een aantal 
afwĳkingen gevonden die karakteristiek waren voor IP-DLBCL en voor nodale DLBCL, wat 
erop duidt dat IP-DLBCL zich onderscheiden van overige DLBCL. De vondst van afwĳkingen 
die karakteristiek waren voor alleen IP-DLBCL van de hersenen en voor alleen IP-DLBCL van 
de testis betekent dat er toch nog enige heterogeniteit binnen IP-DLBCL bestaat.
In de algemene discussie van het onderzoek (��������� �) werd voorgesteld om, op 
basis van de hiervoor besproken resultaten, IP-DLBCL de status van aparte subgroep bin-
nen de DLBCL toe te kennen. Ook werd een model besproken dat probeert te verklaren hoe 
IP-DLBCL ontstaan en wat de rol van het immuunsysteem daarbĳ is. Dit model gaat uit van 
de observatie dat in IP-DLBCL zeer veel mutaties in het IgH gen gegenereerd worden, meer 
dan in andere DLBCL. De mutaties zorgen ervoor dat het geproduceerde eiwit door het 
immuunsysteem als lichaamsvreemd kan worden gezien en een anti-tumor (‘anti-idiotype’) 
immuunreactie kan veroorzaken. Daarom wordt dit eiwit ‘immunogeen’ genoemd. Hoe meer 
mutaties, hoe meer immunogeen het eiwit en hoe hoger de kans op een anti-tumor immuun-
reactie. Omdat IP-DLBCL zo veel mutaties hebben, worden ze zeer snel aangevallen door het 
immuunsysteem. De enige overlevingskans voor deze lymfomen is daarom in de immune-
privileged sites, waar het immuunsysteem is onderdrukt. Hierdoor kunnen deze lymfomen 
ongehinderd doorgroeien. Deze groei hee� echter na verloop van tĳd een zodanig grote 
impact op de omgeving van het lymfoom dat de wankele balans die de onderdrukking van 
het immuunsysteem in stand houdt wordt verstoord. Hierdoor komt toch een immuunreactie 
op gang. Op dat moment begint het proces van immunoediting. Er zal een balans zĳn tussen 
het immuunsysteem dat het lymfoom probeert op te ruimen en het lymfoom dat mechanis-
men aanwendt om te ontsnappen aan het immuunsysteem (zoals verlies van HLA productie). 
Lymfoomcellen die hier succesvol in zĳn, zullen zo ongecontroleerd kunnen groeien en delen, 
met uiteindelĳk als resultaat een lymfoom dat niet meer opgeruimd kan worden door het 
immuunsysteem.
Concluderend toont dit onderzoek aan dat IP-DLBCL beschikken over speciﬁeke mole-
culaire eigenschappen die waarschĳnlĳk aan de basis liggen van hun speciﬁeke lokalisatie en 
biologisch gedrag. De interactie tussen het lymfoom en zĳn omgeving is van grote invloed op 
de uiteindelĳke karakteristieken van het IP-DLBCL. Deze bevindingen ondersteunen de clas-
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bĳ het verzamelen van materiaal en voor de gezelligheid tĳdens mĳn bezoekjes aan het LUMC 
en tĳdens congressen.
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Beste Roel en Richard, zonder jullie zat ik nu waarschĳnlĳk nog naast een antieke compu-
ter te wachten tot Excel eindelĳk mĳn analyse had gerund. Jullie hulp is onmisbaar geweest 
bĳ alle ‘special projects’ zoals het aan het netwerk krĳgen van mĳn laptop en de Mac en het 
doorworstelen van slecht geprogrammeerde scripts met obscure variabelen. Als een analyse 
wat te lang duurde kon ik bĳ jullie ook altĳd terecht voor een discussie over creationisme, 
poezen of de betekenis van de a�orting ICT. Bedankt!
Natuurlĳk wil ik ook mĳn kamergenoten van het eerste uur, Jeroen, Johan, Eugenia en 
Evert-Jan, heel erg bedanken. Ik denk dat wĳ toch wel hebben bewezen wat de meest eﬀec-
tieve kamerindeling is voor zowel serieuze als minder serieuze gesprekken. Ik heb erg veel 
van jullie geleerd, ik hoop dat dat andersom ook zo is geweest. (Ex)kamergenoten/buren/Ed-
collega’s Joost, Çiğdem, Mirjam, Wouter, Michiel, Lukas, Lorian en Mirjam, bedankt voor de 
gezelligheid!
Beste Gustaaf, bedankt voor je hulp bĳ het verzamelen van de klinische gegevens. We heb-
ben interessante gesprekken gehad over de klinische kant van het onderzoek, voor mĳ tot dan 
toe onbekend terrein. Beste Frans, Edo, Jelmer en Anne, jullie wil ik bedanken voor de nut-
tige besprekingen over de array analyse (en de uurtjes ‘theeleuten’). Beste Klaas en Anneke, 
bedankt voor de samenwerking bĳ het chromosoom � array project. Beste Lorian en Tjasso, 
bedankt voor jullie hulp op het O&O lab en bedankt voor de coupes die jullie gesneden en 
gekleurd hebben. Beste Jelle en Edwin, ﬁjn dat jullie altĳd tĳd hadden of maakten als ik weer 
paraﬃnecoupes nodig had (ook als het van die rotblokjes uit Leiden waren). Beste Jan, Clau-
dia en Dicky, bedankt voor jullie hulp bĳ de Ventana kleuringen.
Een eervolle vermelding gaat naar mĳn ouders. Ze konden het destĳds nog niet weten, 
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ondanks dat ik telkens weer met een nieuwe einddatum kwam aanze�en. Het is nu echt 
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ABC activated B cell 
AINR activation-induced non-responsiveness 
APC antigen-presenting cell 
CGH comparative genomic hybridization 
CNS central nervous system 
CTL cytotoxic T cell 
DLBCL diﬀuse large B-cell lymphoma 
ER endoplasmic reticulum 
FDR false discovery rate 
FISH ﬂuorescence in situ hybridization 
FL follicular lymphoma 
GCB germinal center B cell 
HLA human leukocyte antigen 
IgH immunoglobulin heavy chain 
IP-DLBCL immune-privileged site-associated diﬀuse large B-cell lymphoma 
MHC major histocompatibility complex (contains the HLA genes) 
NK cells natural killer cells 
SAM signiﬁcance analysis of microarrays 
SHM somatic hypermutation 
TAM tumor-associated macrophage 
Th (�/�) cells T helper (�/�) cells
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